{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Please give the file name contains PMID list:results-hydroxychloroquine.txt\n",
      "The results-hydroxychloroquine.txt contains 8103 rows in total.\n",
      "There are 7617 rows with PMID.\n",
      "There are 1107 unique PMIDs.\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32307653//?format=pubmed...\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\linay\\JupyterSpace\\CTO\\mylib\\PubMedTerms_useList.py:55: GuessedAtParserWarning: No parser was explicitly specified, so I'm using the best available HTML parser for this system (\"lxml\"). This usually isn't a problem, but if you run this code on another system, or in a different virtual environment, it may use a different parser and behave differently.\n",
      "\n",
      "The code that caused this warning is on line 55 of the file C:\\Users\\linay\\JupyterSpace\\CTO\\mylib\\PubMedTerms_useList.py. To get rid of this warning, pass the additional argument 'features=\"lxml\"' to the BeautifulSoup constructor.\n",
      "\n",
      "  soup = BeautifulSoup(page)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32307653', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*Antiviral responses;*Asthma;*Basigin;*Cellular therapy;*Coronavirus;*Diabetes mellitus;*EMMPRIN;*Invasion;*Lung stem cells;*SARSCoV2', 'MH': 'AngiotensinConverting Enzyme 2;AntiBacterial Agents/*therapeutic use;Azithromycin/*therapeutic use;BLymphocytes/drug effects/immunology/virology;Basigin/antagonists & inhibitors/*genetics/immunology;Betacoronavirus/*drug effects/metabolism/pathogenicity;COVID19;Clinical Trials as Topic;Coronavirus Infections/epidemiology/immunology/*therapy/virology;Gene Expression;HostPathogen Interactions/drug effects/immunology;Humans;Lung/immunology/virology;*Pandemics;PeptidylDipeptidase A/genetics/immunology;Pneumonia, Viral/epidemiology/immunology/*therapy/virology;Protein Binding/drug effects;SARSCoV2;Spike Glycoprotein, Coronavirus/antagonists & inhibitors/*genetics/immunology;*Stem Cell Transplantation;Stem Cells/drug effects/immunology/virology;TLymphocytes/drug effects/immunology/virology;Viral Load/drug effects;DA 2020/06/03 06:00', 'SI': '', 'TI': 'CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem ', 'GR': 'No. 2018/084260/Fundação de Amparo à Pesquisa do Estado de São Paulo/International'}\n",
      "1 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32754463//?format=pubmed...\n",
      "{'PMID': '32754463', 'PT': 'Editorial', 'OT': 'O  NNLM;COVID19;SARSCoV2;pandemic;quarantine;remdesivir;social distancing', 'MH': 'DA 2020/08/06 06:01', 'SI': '', 'TI': 'Preventive and treatment strategies of COVID-19: From community to clinical trials.', 'GR': ''}\n",
      "2 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33384605//?format=pubmed...\n",
      "{'PMID': '33384605', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;ICU admission;antiIL6 signaling agents;clinical improvement;mechanical ventilation;mortality;secondary infections', 'MH': 'DA 2021/01/02 06:01', 'SI': '', 'TI': 'Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A ', 'GR': ''}\n",
      "3 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32565599//?format=pubmed...\n",
      "{'PMID': '32565599', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*Coronavirus disease19;*drug repurposing;*pandemic;*severe acute respiratory syndromecoronavirus2', 'MH': 'Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;COVID19 Vaccines;*Clinical Laboratory Techniques;Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention & ;Developing Countries;Disease Outbreaks;Drug Repositioning;Drug Therapy, Combination;Humans;India/epidemiology;Pandemics;Pneumonia, Viral/diagnosis/epidemiology/*therapy;SARSCoV2;Viral Vaccines/administration & dosage;DA 2020/07/01 06:00', 'SI': '', 'TI': 'COVID-19 pandemic: A review based on current evidence.', 'GR': ''}\n",
      "4 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32964179//?format=pubmed...\n",
      "{'PMID': '32964179', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;anakinra;haemophagocytic lymphohistiocytosis;hyperinflammation', 'MH': 'DA 2020/09/24 06:01', 'SI': '', 'TI': 'Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a ', 'GR': ''}\n",
      "5 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33081817//?format=pubmed...\n",
      "{'PMID': '33081817', 'PT': 'Journal Article;Multicenter Study;Randomized Controlled Trial', 'OT': 'O  NNLM;Azithromycin;Detailed statistical analysis plan;Hydroxychloroquine;Infectious diseases;Intervention;Randomized controlled trial;Safety', 'MH': 'Aged;AntiBacterial Agents/adverse effects/*therapeutic use;Antibiotic Prophylaxis/methods;Antimalarials/adverse effects/*therapeutic use;Azithromycin/adverse effects/*therapeutic use;Betacoronavirus/*drug effects/genetics;COVID19;CaseControl Studies;Coronavirus Infections/epidemiology/*prevention & control/transmission/virology;Denmark/epidemiology;DoubleBlind Method;Drug Therapy, Combination;Female;Hospital Mortality/trends;Hospitalization/statistics & numerical data;Humans;Hydroxychloroquine/adverse effects/*therapeutic use;Intensive Care Units/statistics & numerical data;Intention to Treat Analysis/methods;Male;Noninvasive Ventilation/adverse effects;Pandemics/*prevention & control;Placebos/administration & dosage;Pneumonia, Viral/epidemiology/*prevention & control/transmission/virology;Risk Reduction Behavior;SARSCoV2;DA 2020/11/04 06:00', 'SI': 'ClinicalTrials.gov/NCT04322396', 'TI': 'Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized ', 'GR': ''}\n",
      "6 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33051827//?format=pubmed...\n",
      "{'PMID': '33051827', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;Clinical trials;Early treatment;Treatment as prevention', 'MH': 'DA 2020/10/15 06:01', 'SI': '', 'TI': 'Early Treatment of COVID-19 Disease: A Missed Opportunity.', 'GR': ''}\n",
      "7 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32718560//?format=pubmed...\n",
      "{'PMID': '32718560', 'PT': \"Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*COVID19;*Nitric oxide;*RRx001;*SARSCoV2', 'MH': 'Antihypertensive Agents/therapeutic use;Azetidines/*therapeutic use;Bosentan/therapeutic use;COVID19/*drug therapy/epidemiology/virology;Drug Repositioning/methods/trends;Humans;Lung/drug effects/physiopathology/virology;Nitric Oxide Donors/therapeutic use;Nitro Compounds/*therapeutic use;Pandemics;SARSCoV2/*drug effects/physiology;DA 2020/12/15 06:00', 'SI': '', 'TI': 'Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of ', 'GR': ''}\n",
      "8 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32550705//?format=pubmed...\n",
      "{'PMID': '32550705', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19 diagnostic testing [Supplementary Concept];*Patients;*Therapeutics', 'MH': 'Betacoronavirus;Biomedical Research/*trends;COVID19;Coronavirus Infections/*therapy;Humans;Pandemics;Pneumonia, Viral/*therapy;SARSCoV2;DA 2020/07/24 06:00', 'SI': '', 'TI': 'Treatment and research lines for the patient with COVID-19. What do we have and ', 'GR': ''}\n",
      "9 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32681497//?format=pubmed...\n",
      "{'PMID': '32681497', 'PT': 'Journal Article;Research Support, N.I.H., Extramural;Review', 'OT': 'O  NNLM;*Adultonset Still’s disease;*Antiviral;*COVID19;*Catastrophic antiphospholipid syndrome;*Deferoxamine;*Hemophagocytic lymphohistiocytosis;*Hyperferritinemic;*Iron;*Iron depletion therapy;*Macrophage activation syndrome;*SARSCoV2', 'MH': 'Betacoronavirus/*metabolism;COVID19;*Coronavirus Infections/blood/drug therapy/epidemiology;Ferritins/*blood;Humans;Iron/*blood;Iron Chelating Agents/*therapeutic use;*Iron Overload/blood/drug therapy/epidemiology;*Pandemics;*Pneumonia, Viral/blood/drug therapy/epidemiology;SARSCoV2;DA 2020/08/04 06:00', 'SI': '', 'TI': 'COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion ', 'GR': ''}\n",
      "10 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32360585//?format=pubmed...\n",
      "{'PMID': '32360585', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*Antiviral;*COVID19;*Immunization;*Therapy', 'MH': 'Antiviral Agents/*therapeutic use;Betacoronavirus/drug effects;COVID19;China;Coronavirus Infections/*drug therapy;Humans;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/07/01 06:00', 'SI': '', 'TI': 'Current targeted therapeutics against COVID-19: Based on first-line experience in ', 'GR': ''}\n",
      "11 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32373347//?format=pubmed...\n",
      "{'PMID': '32373347', 'PT': 'Journal Article', 'OT': 'O  NNLM;Cell biology;Molecular biology', 'MH': 'DA 2020/05/07 06:01', 'SI': '', 'TI': 'The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in ', 'GR': ''}\n",
      "12 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32409782//?format=pubmed...\n",
      "{'PMID': '32409782', 'PT': 'Journal Article', 'OT': '', 'MH': '*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*immunology;Glomerulonephritis/*drug therapy/immunology;Humans;Immunosuppressive Agents/*therapeutic use;*Kidney Transplantation;Pandemics;Pneumonia, Viral/drug therapy/*immunology;SARSCoV2;DA 2020/07/01 06:00', 'SI': '', 'TI': 'COVID-19: implications for immunosuppression in kidney disease and transplantation.', 'GR': ''}\n",
      "13 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33317695//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '33317695', 'PT': \"Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*TFEB;*autophagy;*human;*human T cells;*immunology;*inflammation;*spermidine;*vaccine', 'MH': 'Adjuvants, Immunologic/pharmacology;Adult;Aged;Aging/*immunology;Animals;Autophagy/*immunology;Basic HelixLoopHelix Leucine Zipper Transcription Factors/metabolism;CD8Positive TLymphocytes/*immunology;Cell Line, Tumor;Humans;Immunologic Memory/immunology;Interferongamma/blood;Jurkat Cells;Mice;Mice, Inbred C57BL;Mice, Knockout;Middle Aged;Peptide Initiation Factors/metabolism;RNABinding Proteins/metabolism;Respiratory Syncytial Virus Vaccines/*immunology;Respiratory Syncytial Viruses/immunology;Spermidine/blood/*pharmacology;Vaccination;Young Adult;DA 2021/03/17 06:00', 'SI': 'ClinicalTrials.gov/NCT01070407;ClinicalTrials.gov/NCT01296451', 'TI': 'Autophagy in T cells from aged donors is maintained by spermidine and correlates ', 'GR': 'WT_/Wellcome Trust/United Kingdom;WT109665MA/Wellcome/International'}\n",
      "14 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32485610//?format=pubmed...\n",
      "{'PMID': '32485610', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*Adverse drug reactions;*COVID19;*Dietary supplements;*Duchenne muscular dystrophy;*SARSCoV2;*Safety', 'MH': '*Betacoronavirus;COVID19;Coronavirus Infections/complications/*diet therapy;Dietary Supplements/*adverse effects;*Drug Interactions;Humans;Muscular Dystrophy, Duchenne/complications/*diet therapy;Pandemics;Pneumonia, Viral/complications/*diet therapy;SARSCoV2;*Standard of Care;DA 2020/07/21 06:00', 'SI': '', 'TI': 'Safety issues and harmful pharmacological interactions of nutritional supplements in ', 'GR': ''}\n",
      "15 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33062949//?format=pubmed...\n",
      "{'PMID': '33062949', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'DA 2020/10/17 06:01', 'SI': '', 'TI': 'Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19.', 'GR': ''}\n",
      "16 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32984620//?format=pubmed...\n",
      "{'PMID': '32984620', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Antisense;Aptamers;Biotechnology;Covid19;DNAzymes;Epidemiology;Microbiology;Molecular biology;Nucleic acid based therapy;Oligonucleotide;Regenerative medicine;Ribozymes;SARSCoV2;Virology;siRNA', 'MH': 'DA 2020/09/29 06:01', 'SI': '', 'TI': 'Nucleic acid-based therapy for coronavirus disease 2019.', 'GR': ''}\n",
      "17 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32979360//?format=pubmed...\n",
      "{'PMID': '32979360', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Cell therapy;Clinical trials;Coronavirus;Cytokine storm;Immunomodulatory effects', 'MH': 'COVID19/*immunology/*therapy;Humans;Immunomodulation/*physiology;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/*immunology;SARSCoV2/*immunology;DA 2020/12/15 06:00', 'SI': '', 'TI': 'Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of ', 'GR': ''}\n",
      "18 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33166179//?format=pubmed...\n",
      "{'PMID': '33166179', 'PT': 'Journal Article', 'OT': '', 'MH': 'DA 2020/11/10 06:00', 'SI': 'ClinicalTrials.gov/NCT04329832', 'TI': 'Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): ', 'GR': 'U01 HL123018/HL/NHLBI NIH HHS/United States;UL1 RR025764/RR/NCRR NIH HHS/United States;U01 HL123009/HL/NHLBI NIH HHS/United States;UL1 TR002538/TR/NCATS NIH HHS/United States;K23 GM129661/GM/NIGMS NIH HHS/United States;UL1 TR000105/TR/NCATS NIH HHS/United States;U01 HL143505/HL/NHLBI NIH HHS/United States;UL1 TR001067/TR/NCATS NIH HHS/United States'}\n",
      "19 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33022293//?format=pubmed...\n",
      "{'PMID': '33022293', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19;*Prophylaxis;*Repurposed chemotherapy;*SARSCoV2', 'MH': 'DA 2020/10/07 06:00', 'SI': '', 'TI': 'Clinical trial protocols of repurposed prophylaxis for COVID-19: A review.', 'GR': ''}\n",
      "20 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33476760//?format=pubmed...\n",
      "{'PMID': '33476760', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Antivirals;COVID19;Clinical trials;Immunomodulators;Prevention;SARSCoV2;Vaccines', 'MH': 'Antiviral Agents/therapeutic use;COVID19/*prevention & control;*Clinical Trials as Topic;*Drug Development;*Drug Repositioning;Humans;Immunologic Factors/therapeutic use;SARSCoV2;Vaccines/therapeutic use;DA 2021/04/24 06:00', 'SI': '', 'TI': 'Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early ', 'GR': ''}\n",
      "21 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33072111//?format=pubmed...\n",
      "{'PMID': '33072111', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*antibody;*convalescent plasma therapy;*coronavirus disease 2019;*immunotherapy;*severe acute respiratory syndrome coronavirus2', 'MH': '*Antibodies, Neutralizing/immunology/therapeutic use;*Antibodies, Viral/immunology/therapeutic use;Betacoronavirus/*immunology;COVID19;*Coronavirus Infections/epidemiology/immunology/therapy;Humans;Immunization, Passive;*Pandemics;Plasma/immunology;*Pneumonia, Viral/epidemiology/immunology/therapy;Randomized Controlled Trials as Topic;SARSCoV2;DA 2020/10/27 06:00', 'SI': '', 'TI': 'Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 ', 'GR': 'CIHR/Canada'}\n",
      "22 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32737471//?format=pubmed...\n",
      "{'PMID': '32737471', 'PT': 'Journal Article', 'OT': 'O  NNLM;3CL protease;SARSCoV2;Shuanghuanglian oral liquid;baicalein;baicalin;traditional Chinese medicines', 'MH': 'Administration, Oral;Animals;Antiviral Agents/chemistry/pharmacology;Betacoronavirus/*drug effects/physiology;COVID19;Chlorocebus aethiops;*Coronavirus Infections/drug therapy/virology;*Drugs, Chinese Herbal/chemistry/pharmacology;Enzyme Assays;*Flavanones/chemistry/pharmacokinetics;*Flavonoids/chemistry/pharmacokinetics;Humans;*Pandemics;*Pneumonia, Viral/drug therapy/virology;SARSCoV2;Vero Cells;Virus Replication/*drug effects/physiology;DA 2020/09/09 06:00', 'SI': '', 'TI': 'Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ', 'GR': ''}\n",
      "23 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32589146//?format=pubmed...\n",
      "{'PMID': '32589146', 'PT': \"Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*COVID19;*coronavirus;*cure rate model;*restricted mean survival time;*sample size adjustment;*terminal event;*type I error rate', 'MH': 'Adenosine Monophosphate/*analogs & derivatives/therapeutic use;Alanine/*analogs & derivatives/therapeutic use;COVID19/drug therapy;Coronavirus Infections/drug therapy;Data Interpretation, Statistical;Drug Therapy, Combination;Humans;Lopinavir/*therapeutic use;Randomized Controlled Trials as Topic/*methods;Research Design;Ritonavir/*therapeutic use;Treatment Outcome;DA 2020/07/23 06:00', 'SI': '', 'TI': 'Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With ', 'GR': ''}\n",
      "24 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33020111//?format=pubmed...\n",
      "{'PMID': '33020111', 'PT': \"Journal Article;Observational Study;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*COVID19;*clinical trials;*infectious diseases', 'MH': 'Betacoronavirus/isolation & purification;*Biomedical Research/organization & administration/statistics & numerical data;COVID19;*Coronavirus Infections/epidemiology/therapy;Eligibility Determination;Female;Health Services Accessibility/statistics & numerical data;Hospitalization/statistics & numerical data;Humans;Male;Middle Aged;*Pandemics;*Patient Selection;*Pneumonia, Viral/epidemiology/therapy;Prospective Studies;*Randomized Controlled Trials as Topic/methods/statistics & numerical data;Registries/statistics & numerical data;SARSCoV2;United Kingdom;DA 2020/10/21 06:00', 'SI': '', 'TI': 'How achievable are COVID-19 clinical trial recruitment targets? A UK observational ', 'GR': 'MC_UU_00002/15/MRC_/Medical Research Council/United Kingdom;MR/P008801/1/MRC_/Medical Research Council/United Kingdom'}\n",
      "25 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33311551//?format=pubmed...\n",
      "{'PMID': '33311551', 'PT': \"Clinical Trial;Journal Article;Multicenter Study;Research Support, NonU.S. Gov't\", 'OT': '', 'MH': 'Aged;Antibodies, Monoclonal, Humanized/*administration & dosage;*COVID19/drug therapy/mortality;DiseaseFree Survival;Female;*Hospitalization;Humans;Interleukin1beta/*antagonists & inhibitors;Male;Middle Aged;Oxygen/administration & dosage;Prospective Studies;*SARSCoV2;Survival Rate;DA 2020/12/22 06:00', 'SI': '', 'TI': 'Blockage of interleukin-1β with canakinumab in patients with Covid-19.', 'GR': ''}\n",
      "26 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33486200//?format=pubmed...\n",
      "{'PMID': '33486200', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;3CL protease;ACE2 receptor;COVID19;Cathepsin L proteinase;Coronavirus;Inhibitors. contents;RdRp;SARSCoV2;Spike glycoprotein;TMPRSS2', 'MH': 'Animals;Antiviral Agents/chemistry/*therapeutic use;COVID19/*drug therapy/epidemiology;Drug Discovery;Humans;Pandemics;Protease Inhibitors/chemistry/therapeutic use;SARSCoV2/*drug effects/physiology;Spike Glycoprotein, Coronavirus/antagonists & inhibitors;DA 2021/03/10 06:00', 'SI': '', 'TI': 'The race to treat COVID-19: Potential therapeutic agents for the prevention and ', 'GR': ''}\n",
      "27 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32838150//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32838150', 'PT': 'Journal Article', 'OT': 'O  NNLM;Asian;Azithromycin;COVID19;Cardiac arrhythmia;Hydroxychloroquine;Ventricular arrhythmia', 'MH': 'DA 2020/08/25 06:00', 'SI': '', 'TI': 'Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on ', 'GR': ''}\n",
      "28 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32983179//?format=pubmed...\n",
      "{'PMID': '32983179', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*COVID19;*SARSCoV2;*chloroquine;*hydroxychloroquine;*immune modulation', 'MH': 'Antimalarials/adverse effects/pharmacology/*therapeutic use;Antiviral Agents/adverse effects/pharmacology/*therapeutic use;Betacoronavirus/*drug effects;COVID19;Coronavirus Infections/*drug therapy/immunology/virology;Drug Repositioning/methods;Humans;Hydroxychloroquine/adverse effects/pharmacology/*therapeutic use;Immunologic Factors/adverse effects/pharmacology/*therapeutic use;*Immunomodulation;Pandemics;Pneumonia, Viral/*drug therapy/immunology/virology;SARSCoV2;DA 2020/10/21 06:00', 'SI': '', 'TI': 'Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case ', 'GR': ''}\n",
      "29 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32785162//?format=pubmed...\n",
      "{'PMID': '32785162', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;AntiPD1 monoclonal antibody;COVID19;SARSCoV2;cancer;immunecheckpoint inhibitors;immunotherapy', 'MH': 'DA 2020/08/14 06:01', 'SI': '', 'TI': 'Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based ', 'GR': ''}\n",
      "30 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32699031//?format=pubmed...\n",
      "{'PMID': '32699031', 'PT': \"Journal Article;Observational Study;Research Support, NonU.S. Gov't\", 'OT': '', 'MH': 'Adenosine Monophosphate/analogs & derivatives/therapeutic use;Age Factors;Aged;Alanine/analogs & derivatives/therapeutic use;Betacoronavirus/pathogenicity;COVID19;Clinical DecisionMaking;Coronavirus Infections/complications/diagnosis/*drug therapy/mortality;Drug Therapy, Combination/methods/statistics & numerical data;Drug Utilization/*statistics & numerical data;FollowUp Studies;Glucocorticoids/therapeutic use;Healthcare Disparities/*statistics & numerical data;Hospital Mortality;Humans;Hydroxychloroquine/therapeutic use;Male;Middle Aged;Neoplasms/complications/*mortality;Pandemics;Pneumonia, Viral/complications/diagnosis/*drug therapy/mortality;Risk Factors;SARSCoV2;Severity of Illness Index;Sex Factors;Treatment Outcome;United States/epidemiology;DA 2020/10/21 06:00', 'SI': '', 'TI': 'Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: ', 'GR': 'UL1 TR000445/TR/NCATS NIH HHS/United States;T32 HG008341/HG/NHI NIH HHS/United States;U01 CA231840/CA/NCI NIH HHS/United States;UG1 CA189974/CA/NCI NIH HHS/United States;UG1 CA189828/CA/NCI NIH HHS/United States;P30 CA013696/CA/NCI NIH HHS/United States;P30 CA068485/CA/NCI NIH HHS/United States;P30 CA054174/CA/NCI NIH HHS/United States;T32 CA203703/CA/NCI NIH HHS/United States;T32 CA009515/CA/NCI NIH HHS/United States;U10 CA180888/CA/NCI NIH HHS/United States;P30 CA196521/CA/NCI NIH HHS/United States'}\n",
      "31 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33156812//?format=pubmed...\n",
      "{'PMID': '33156812', 'PT': 'Journal Article', 'OT': 'O  NNLM;Brazil;COVID19;SARSCoV2;chronic disease;cohort;immunemediated rheumatic diseases;immunology;infection rate;inflammatory;morbidity;mortality;prospective study;registry', 'MH': 'DA 2020/11/07 06:01', 'SI': '', 'TI': 'A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases ', 'GR': ''}\n",
      "32 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33549263//?format=pubmed...\n",
      "{'PMID': '33549263', 'PT': 'Journal Article;Review', 'OT': '', 'MH': '*Biological Variation, Population;*COVID19/diagnosis/therapy;COVID19 Testing;Genetic Predisposition to Disease;Humans;*Precision Medicine;Severity of Illness Index;Treatment Outcome;DA 2021/02/26 06:00', 'SI': '', 'TI': 'COVID-19: Understanding Inter-Individual Variability and Implications for Precision ', 'GR': 'K23 HL143161/HL/NHLBI NIH HHS/United States'}\n",
      "33 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32522282//?format=pubmed...\n",
      "{'PMID': '32522282', 'PT': 'Clinical Trial Protocol;Letter', 'OT': 'O  NNLM;COVID19;Randomised controlled trial;azithromycin;hydroxychloroquine;protocol;respiratory infections', 'MH': 'Antiviral Agents/*administration & dosage/adverse effects;Azithromycin/*administration & dosage/adverse effects;Betacoronavirus/*drug effects/pathogenicity;COVID19;Coronavirus Infections/diagnosis/*drug therapy/mortality/virology;Critical Care;Denmark;DoubleBlind Method;Drug Administration Schedule;Hospital Mortality;HostPathogen Interactions;Humans;Hydroxychloroquine/*administration & dosage/adverse effects;*Inpatients;Length of Stay;Multicenter Studies as Topic;Noninvasive Ventilation;Pandemics;*Patient Admission;Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology;Randomized Controlled Trials as Topic;SARSCoV2;Severity of Illness Index;Time Factors;Treatment Outcome;DA 2020/06/18 06:00', 'SI': 'ClinicalTrials.gov/NCT04322396', 'TI': 'Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised ', 'GR': 'NNF20SA0062834/Novo Nordisk Fonden/'}\n",
      "34 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32766679//?format=pubmed...\n",
      "{'PMID': '32766679', 'PT': 'Comment;Journal Article', 'OT': '', 'MH': '*COVID19;*Coronavirus Infections/epidemiology;Humans;Hydroxychloroquine;Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/12/17 06:00', 'SI': '', 'TI': 'Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment ', 'GR': ''}\n",
      "35 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32973818//?format=pubmed...\n",
      "{'PMID': '32973818', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19;*PI3K;*SARSCoV2;*inflammation;*therapy', 'MH': 'AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/therapeutic use;AntiInflammatory Agents/therapeutic use;Antirheumatic Agents/therapeutic use;Antiviral Agents/therapeutic use;*Betacoronavirus;Butyrophenones/pharmacology/therapeutic use;COVID19;Class I Phosphatidylinositol 3Kinases/*antagonists & inhibitors/metabolism;Coronavirus Infections/*drug therapy/virology;Drug Repositioning/*methods;Humans;Inflammation/drug therapy/immunology;Interleukin6/antagonists & inhibitors/blood;Molecular Targeted Therapy/*methods;Pandemics;PeptidylDipeptidase A/metabolism;Piperidines/pharmacology/therapeutic use;Pneumonia, Viral/*drug therapy/virology;Purines/pharmacology/therapeutic use;Quinazolinones/pharmacology/therapeutic use;SARSCoV2;DA 2020/10/21 06:00', 'SI': '', 'TI': 'PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.', 'GR': ''}\n",
      "36 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32992245//?format=pubmed...\n",
      "{'PMID': '32992245', 'PT': \"Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*Antiviral;*COVID19;*Coronavirus;*Repurposed drugs;*SARSCoV2', 'MH': 'Antiviral Agents/chemistry/*therapeutic use;COVID19/immunology/*therapy;COVID19 Vaccines/*immunology;*Drug Repositioning;Humans;SARSCoV2/*drug effects/immunology;DA 2020/12/22 06:00', 'SI': '', 'TI': 'COVID-19 therapy: What weapons do we bring into battle?', 'GR': ''}\n",
      "37 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33158051//?format=pubmed...\n",
      "{'PMID': '33158051', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;SARSCoV2;coinfection;comorbidity;drugs;host response;integrative genomics;therapeutics;vaccines', 'MH': 'DA 2020/11/08 06:01', 'SI': '', 'TI': 'Threading the Pieces Together: Integrative Perspective on SARS-CoV-2.', 'GR': 'MLP2005,2020/Council of Scientific and Industrial Research/'}\n",
      "38 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32203970//?format=pubmed...\n",
      "{'PMID': '32203970', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*Angiotensin receptor blockers;*Angiotensinconverting enzyme inhibitors;*COVID19;*Renal and cardiac side effects;*SARSCoV2;*Severe acute respiratory syndrome coronavirus', 'MH': 'Angiotensin Receptor Antagonists;AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors;Angiotensins/*antagonists & inhibitors;Betacoronavirus/physiology;COVID19;Coronavirus Infections/*complications;Humans;Kidney/virology;Kidney Diseases/*complications/*drug therapy;Kidney Transplantation;Nephrologists;Pandemics;PeptidylDipeptidase A;Pneumonia, Viral/*complications;Renal Dialysis;SARSCoV2;Virus Replication;DA 2020/05/28 06:00', 'SI': '', 'TI': 'Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse ', 'GR': ''}\n",
      "39 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32873977//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32873977', 'PT': 'Journal Article', 'OT': '', 'MH': 'COVID19;Clinical Trials as Topic/*standards;Coronavirus Infections/*epidemiology;Humans;Informed Consent/standards;*Pandemics;Patient Selection;Pneumonia, Viral/*epidemiology;Quality Improvement;Telemedicine/standards;DA 2020/10/21 06:00', 'SI': '', 'TI': 'The COVID-19 pandemic: a catalyst to improve clinical trials.', 'GR': ''}\n",
      "40 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32801052//?format=pubmed...\n",
      "{'PMID': '32801052', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'DA 2020/08/18 06:00', 'SI': '', 'TI': 'Derivatization and combination therapy of current COVID-19 therapeutic agents: a ', 'GR': ''}\n",
      "41 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33110944//?format=pubmed...\n",
      "{'PMID': '33110944', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;Chloroquine;Randomised Clinical Trial;SARSCoV2;Vietnam;coronaviruses', 'MH': 'DA 2020/10/29 06:01', 'SI': 'ClinicalTrials.gov/NCT04328493', 'TI': 'A multi centre randomized open label trial of chloroquine for the treatment of ', 'GR': ''}\n",
      "42 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33272355//?format=pubmed...\n",
      "{'PMID': '33272355', 'PT': \"Comparative Study;Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*COVID19;*coronavirus;*death;*outcome;*risk factors', 'MH': 'Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;COVID19;Comorbidity;Coronavirus/*isolation & purification;Coronavirus Infections/*diagnosis/mortality/therapy;Dyspnea/epidemiology;Female;France/epidemiology;Humans;Inflammation/epidemiology;Intensive Care Units/*statistics & numerical data;Male;Middle Aged;Obesity/epidemiology;Pandemics;Patient Admission/*statistics & numerical data;Pneumonia, Viral/*diagnosis/mortality/therapy;Prospective Studies;Risk Factors;Severity of Illness Index;Sex Factors;Survival Analysis;Young Adult;DA 2020/12/15 06:00', 'SI': '', 'TI': 'Clinical characteristics and risk factors associated with severe COVID-19: ', 'GR': ''}\n",
      "43 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32665963//?format=pubmed...\n",
      "{'PMID': '32665963', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'DA 2020/07/16 06:01', 'SI': '', 'TI': 'Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options.', 'GR': ''}\n",
      "44 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32585805//?format=pubmed...\n",
      "{'PMID': '32585805', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;SARSCoV2;convalescent plasma;drug repurposing;stem cell therapy;vaccine interventions', 'MH': 'DA 2020/06/27 06:01', 'SI': '', 'TI': 'Emerging Prevention and Treatment Strategies to Control COVID-19.', 'GR': ''}\n",
      "45 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32840231//?format=pubmed...\n",
      "{'PMID': '32840231', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Corona virus;Regenerative medicine;Severe infections;Treatment options', 'MH': 'DA 2020/08/26 06:01', 'SI': '', 'TI': 'Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 ', 'GR': ''}\n",
      "46 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32882823//?format=pubmed...\n",
      "{'PMID': '32882823', 'PT': 'Journal Article', 'OT': 'O  NNLM;Bioinformatics;COVID19;IFN response;SARSCoV;SARSCoV2;SARSMERS;fatty acid synthesis;gene expressions;immune response;influenza A;influenza B;pathway analysis;rhinovirus', 'MH': 'DA 2020/09/05 06:01', 'SI': '', 'TI': 'Computational and Transcriptome Analyses Revealed Preferential Induction of ', 'GR': 'QB13/Qatar Biomedical Research institute/'}\n",
      "47 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33485973//?format=pubmed...\n",
      "{'PMID': '33485973', 'PT': 'Journal Article;Systematic Review', 'OT': 'O  NNLM;Active ingredients;Broadspectrum antiviral;Chinese herbal medicine;Organ protection;SARSCov2', 'MH': 'Animals;COVID19/*drug therapy;Drugs, Chinese Herbal/*therapeutic use;Humans;*Medicine, Chinese Traditional;*SARSCoV2;DA 2021/02/16 06:00', 'SI': '', 'TI': 'Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.', 'GR': ''}\n",
      "48 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32798602//?format=pubmed...\n",
      "{'PMID': '32798602', 'PT': 'Journal Article;Research Support, N.I.H., Extramural;Research Support, N.I.H., Intramural', 'OT': 'O  NNLM;*Antiviral;*Ebola;*Lysosomotropic;*Machine learning', 'MH': 'DA 2020/08/18 06:00', 'SI': '', 'TI': 'Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.', 'GR': 'R21 TR001718/TR/NCATS NIH HHS/United States;R43 GM122196/GM/NIGMS NIH HHS/United States;R43 ES031038/ES/NIEHS NIH HHS/United States;R44 GM122196/GM/NIGMS NIH HHS/United States'}\n",
      "49 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32923374//?format=pubmed...\n",
      "{'PMID': '32923374', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'DA 2020/09/15 06:01', 'SI': '', 'TI': 'Potential use of polyphenols in the battle against COVID-19.', 'GR': 'R01 AT010271/AT/NCCIH NIH HHS/United States'}\n",
      "50 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32939324//?format=pubmed...\n",
      "{'PMID': '32939324', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*Coronavirus;*Covid19;*SarsCoV2;*cellular;*humoral;*immune response;*immunity', 'MH': 'COVID19/diagnosis/*immunology/virology;Host Microbial Interactions/*immunology;Humans;Immunity, Cellular;Immunity, Humoral;Middle East Respiratory Syndrome Coronavirus/immunology;Protective Factors;Risk Factors;SARS Virus/immunology;SARSCoV2/*immunology;Severity of Illness Index;DA 2020/09/18 06:01', 'SI': '', 'TI': 'Immune responses during COVID-19 infection.', 'GR': ''}\n",
      "51 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32880078//?format=pubmed...\n",
      "{'PMID': '32880078', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Computational;Coronavirus;Drug;SARSCoV2;Vaccine', 'MH': 'Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/virology;Computational Biology/methods;Drug Discovery/methods;Drug Repositioning/methods;Humans;Pandemics/prevention & control;SARSCoV2/*drug effects;DA 2021/02/18 06:00', 'SI': '', 'TI': 'Therapeutics for COVID-19: from computation to practices-where we are, where we are ', 'GR': ''}\n",
      "52 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32468014//?format=pubmed...\n",
      "{'PMID': '32468014', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'Angiotensin II Type 1 Receptor Blockers/classification/therapeutic use;AngiotensinConverting Enzyme 2;Betacoronavirus/*drug effects/pathogenicity/physiology;Bromhexine/pharmacology/therapeutic use;COVID19;Chlorpromazine/pharmacology/therapeutic use;Clinical Trials as Topic/methods;Coronavirus Infections/*drug therapy/epidemiology/mortality;Diminazene/pharmacology/therapeutic use;*Drug Repositioning/methods/standards/trends;Gabexate/analogs & derivatives/pharmacology/therapeutic use;Humans;Pandemics;PeptidylDipeptidase A/chemistry/metabolism/therapeutic use;Pneumonia, Viral/*drug therapy/epidemiology/mortality;Receptor, Angiotensin, Type 1/metabolism;Recombinant Proteins/chemistry/therapeutic use;SARSCoV2;Signal Transduction/drug effects;Virus Internalization/*drug effects;DA 2020/07/02 06:00', 'SI': '', 'TI': 'Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights ', 'GR': ''}\n",
      "53 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32849833//?format=pubmed...\n",
      "{'PMID': '32849833', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;Indian population;SARSCoV2;angiotensin converting enzyme 2;killer cell immunoglobulinlike receptors;microRNA', 'MH': 'DA 2020/08/28 06:01', 'SI': '', 'TI': 'The Enigma of Low COVID-19 Fatality Rate in India.', 'GR': ''}\n",
      "54 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32918656//?format=pubmed...\n",
      "{'PMID': '32918656', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19;*Cardiovascular therapy;*Drug interactions;*Lopinavirritonavir;*SARSCoV2', 'MH': 'Anticoagulants/therapeutic use;COVID19/*drug therapy;Drug Interactions;Drug Therapy, Combination;Heart Diseases/*drug therapy;Humans;Hypolipidemic Agents/therapeutic use;Lopinavir/*administration & dosage;Platelet Aggregation Inhibitors/therapeutic use;Ritonavir/*administration & dosage;*SARSCoV2;DA 2021/05/18 06:00', 'SI': '', 'TI': 'Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with ', 'GR': ''}\n",
      "55 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32450198//?format=pubmed...\n",
      "{'PMID': '32450198', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Chloroquine;Hydroxychloroquine;Pandemic;SARSCoV2', 'MH': 'AngiotensinConverting Enzyme 2;Antiviral Agents/*pharmacology;Betacoronavirus/*metabolism;COVID19;Chloroquine/*pharmacology;Coronavirus Infections/*drug therapy/metabolism;*Drug Repositioning;Humans;Hydroxychloroquine/*pharmacology;*Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*drug therapy/metabolism;SARSCoV2;DA 2020/08/22 06:00', 'SI': '', 'TI': 'A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing ', 'GR': ''}\n",
      "56 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32821381//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32821381', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;chloroquine;evidence;hydroxychloroquine;review', 'MH': 'DA 2020/08/22 06:01', 'SI': '', 'TI': 'Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a ', 'GR': ''}\n",
      "57 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32946870//?format=pubmed...\n",
      "{'PMID': '32946870', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Methylxanthines;Pentoxifylline and caffeine', 'MH': 'AntiInflammatory Agents, NonSteroidal/pharmacology/therapeutic use;COVID19;Caffeine/pharmacology/therapeutic use;Coronavirus Infections/complications/*drug therapy;Humans;Infant, Newborn;Infant, Premature;Inflammation/drug therapy/etiology;*Pandemics;Pentoxifylline/pharmacology/*therapeutic use;Pneumonia, Viral/complications/*drug therapy;Xanthines/*pharmacology/*therapeutic use;DA 2020/11/06 06:00', 'SI': '', 'TI': 'Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 ', 'GR': ''}\n",
      "58 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32773471//?format=pubmed...\n",
      "{'PMID': '32773471', 'PT': 'Journal Article;Observational Study', 'OT': '', 'MH': 'Adult;AntiHIV Agents/therapeutic use;Betacoronavirus;CD4 Lymphocyte Count;COVID19;Coronavirus Infections/*mortality/*physiopathology;Female;HIV Infections/*complications/drug therapy;Humans;Incidence;Male;Middle Aged;Pandemics;Pneumonia, Viral/*mortality/*physiopathology;Prospective Studies;Risk Factors;SARSCoV2;Spain/epidemiology;DA 2020/09/17 06:00', 'SI': '', 'TI': 'Clinical characteristics, risk factors, and incidence of symptomatic coronavirus ', 'GR': ''}\n",
      "59 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33093056//?format=pubmed...\n",
      "{'PMID': '33093056', 'PT': 'Clinical Trial, Phase II;Journal Article;Multicenter Study;Randomized Controlled Trial', 'OT': '', 'MH': 'Adult;Antibodies, Neutralizing/blood;Antibodies, Viral/blood;Betacoronavirus;COVID19;Coronavirus Infections/mortality/*therapy;Disease Progression;Female;Humans;Immunization, Passive;India;Male;Middle Aged;Pandemics;Pneumonia, Viral/mortality/*therapy;SARSCoV2;Treatment Failure;DA 2020/11/06 06:00', 'SI': 'CTRI/CTRI/2020/04/024775', 'TI': 'Convalescent plasma in the management of moderate covid-19 in adults in India: open ', 'GR': ''}\n",
      "60 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33408023//?format=pubmed...\n",
      "{'PMID': '33408023', 'PT': 'Letter', 'OT': '', 'MH': 'DA 2021/01/08 06:00', 'SI': '', 'TI': 'Hydroxychloroquine (HCQ): real treatment or false hope?', 'GR': ''}\n",
      "61 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33549625//?format=pubmed...\n",
      "{'PMID': '33549625', 'PT': 'Comment;Letter', 'OT': '', 'MH': 'Amides;*COVID19;Humans;Imatinib Mesylate/therapeutic use;Pyrazines;SARSCoV2;Treatment Outcome;DA 2021/05/01 06:00', 'SI': '', 'TI': 'Early clinical experience with imatinib in COVID-19: Searching for a dual effect.', 'GR': ''}\n",
      "62 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33079850//?format=pubmed...\n",
      "{'PMID': '33079850', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'AntiInflammatory Agents/adverse effects/*therapeutic use;Anticoagulants/adverse effects/*therapeutic use;Betacoronavirus/*pathogenicity;Biomarkers/blood;Blood Coagulation/*drug effects;COVID19;Coronavirus Infections/blood/mortality/*therapy/virology;EvidenceBased Medicine;Fibrin Fibrinogen Degradation Products/analysis;Hospital Mortality;HostPathogen Interactions;Humans;Inflammation/blood/mortality/*therapy/virology;Inflammation Mediators/blood;Pandemics;Pneumonia, Viral/blood/mortality/*therapy/virology;Prognosis;Pulmonary Embolism/blood/mortality/*therapy/virology;Risk Factors;SARSCoV2;Venous Thromboembolism/blood/mortality/*therapy/virology;Venous Thrombosis/blood/mortality/*therapy/virology;DA 2020/10/29 06:00', 'SI': '', 'TI': 'COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already ', 'GR': ''}\n",
      "63 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33013067//?format=pubmed...\n",
      "{'PMID': '33013067', 'PT': 'Journal Article', 'OT': '', 'MH': 'DA 2020/10/06 06:01', 'SI': '', 'TI': 'Anti-corona Drugs: Current Scenario.', 'GR': ''}\n",
      "64 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33072773//?format=pubmed...\n",
      "{'PMID': '33072773', 'PT': 'Journal Article', 'OT': 'O  NNLM;ARDS;COVID  19;MERS (Middle East respiratory syndrome);SARS;SARS  CoV2;antifibrotics;fibrosis', 'MH': 'DA 2020/10/20 06:01', 'SI': '', 'TI': 'Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.', 'GR': 'K08 HL141623/HL/NHLBI NIH HHS/United States'}\n",
      "65 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32535188//?format=pubmed...\n",
      "{'PMID': '32535188', 'PT': 'Clinical Trial;Journal Article', 'OT': 'O  NNLM;*ARDS;*COVID19;*Infection;*RALE score', 'MH': 'Age Factors;Aged;Betacoronavirus/immunology/pathogenicity;COVID19;Comorbidity;Coronary Disease/*diagnosis/epidemiology/immunology/mortality;Coronavirus Infections/*diagnosis/epidemiology/immunology/mortality;Diabetes Mellitus/*diagnosis/epidemiology/immunology/mortality;Female;Hospitalization;Humans;Hypertension/*diagnosis/epidemiology/immunology/mortality;Infectious Disease Incubation Period;Italy/epidemiology;Kidney Failure, Chronic/*diagnosis/epidemiology/immunology/mortality;Lymphocyte Count;Lymphocytes/immunology/pathology/virology;Male;Middle Aged;Pandemics;Pneumonia, Viral/*diagnosis/epidemiology/immunology/mortality;Pulmonary Edema/*diagnosis/epidemiology/immunology/mortality;Risk Factors;SARSCoV2;Severe Acute Respiratory Syndrome/*diagnosis/epidemiology/immunology/mortality;Severity of Illness Index;Survival Analysis;DA 2020/07/22 06:00', 'SI': '', 'TI': 'Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy.', 'GR': ''}\n",
      "66 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32871342//?format=pubmed...\n",
      "{'PMID': '32871342', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Azithromycin;Broadspectrum therapeutic;COVID19', 'MH': 'Animals;AntiInflammatory Agents/adverse effects/*therapeutic use;Antiviral Agents/adverse effects/*therapeutic use;Azithromycin/adverse effects/*therapeutic use;Betacoronavirus;COVID19;Cell Line, Tumor;Coronavirus Infections/*drug therapy;Humans;Immunologic Factors/adverse effects/therapeutic use;Macrophages/metabolism;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;DA 2020/11/18 06:00', 'SI': '', 'TI': 'Azithromycin: The First Broad-spectrum Therapeutic.', 'GR': ''}\n",
      "67 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32867852//?format=pubmed...\n",
      "{'PMID': '32867852', 'PT': 'Clinical Trial Protocol;Letter;Randomized Controlled Trial', 'OT': 'O  NNLM;COVID19;Randomised controlled trial;health personnel;hydroxychloroquine;protocol', 'MH': 'Betacoronavirus;COVID19;Chemoprevention;Coronavirus Infections/*prevention & control/transmission;Enzyme Inhibitors/*therapeutic use;*Health Personnel;Humans;Hydroxychloroquine/*therapeutic use;India;Infectious Disease Transmission, PatienttoProfessional/*prevention & control;Occupational Diseases/*prevention & control;Pandemics/*prevention & control;*Personal Protective Equipment;Pneumonia, Viral/*prevention & control/transmission;SARSCoV2;DA 2020/09/04 06:00', 'SI': '', 'TI': 'Hydroxychloroquine plus personal protective equipment versus standard personal ', 'GR': ''}\n",
      "68 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32862111//?format=pubmed...\n",
      "{'PMID': '32862111', 'PT': 'Journal Article;Randomized Controlled Trial', 'OT': 'O  NNLM;COVID19;Interferon β;Iran;SARSCOV2', 'MH': 'Aged;Antiviral Agents/administration & dosage/adverse effects/*therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/immunology;Drug Administration Schedule;Drug Therapy, Combination;Female;Humans;Injections, Subcutaneous;Interferon beta1b/administration & dosage/adverse effects/*therapeutic use;KaplanMeier Estimate;Male;Methylprednisolone/administration & dosage/therapeutic use;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/immunology;SARSCoV2;Severity of Illness Index;Treatment Outcome;DA 2020/11/24 06:00', 'SI': '', 'TI': 'Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial.', 'GR': ''}\n",
      "69 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32278065//?format=pubmed...\n",
      "{'PMID': '32278065', 'PT': 'Journal Article;Systematic Review', 'OT': 'O  NNLM;*ACE2;*AngiotensinConverting Enzyme 2;*COVID19;*Diarrhea;*Epidemiology;*SARSCoV2;*TMPRSS2', 'MH': 'AngiotensinConverting Enzyme 2;Betacoronavirus/*isolation & purification;COVID19;Child;Coronavirus Infections/*complications;Diarrhea/*epidemiology/pathology/*physiopathology/therapy;*Disease Management;Disease Transmission, Infectious/prevention & control;Feces/*virology;Humans;Incidence;Infection Control/methods;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/*complications;SARSCoV2;Serine Endopeptidases/metabolism;Spike Glycoprotein, Coronavirus/metabolism;Virus Attachment;Virus Internalization;DA 2020/07/01 06:00', 'SI': '', 'TI': 'Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and ', 'GR': ''}\n",
      "70 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32674818//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32674818', 'PT': 'Journal Article;Multicenter Study', 'OT': 'O  NNLM;Angiotensinconverting enzyme inhibitors;COVID19;angiotensin II receptor blockers;nursing home residents;statins', 'MH': 'Aged;Aged, 80 and over;Angiotensin Receptor Antagonists/*administration & dosage;AngiotensinConverting Enzyme Inhibitors/*administration & dosage;Belgium/epidemiology;COVID19;Cause of Death;Cohort Studies;Coronavirus Infections/*drug therapy/*epidemiology;Female;Geriatric Assessment;Homes for the Aged/statistics & numerical data;Humans;HydroxymethylglutarylCoA Reductase Inhibitors/*administration & dosage;Logistic Models;Male;Nursing Homes/statistics & numerical data;Odds Ratio;Pandemics/statistics & numerical data;Pneumonia, Viral/*drug therapy/*epidemiology;Retrospective Studies;Risk Assessment;Severity of Illness Index;Survival Rate;Treatment Outcome;DA 2020/07/31 06:00', 'SI': '', 'TI': 'The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection ', 'GR': \"171/ALZS_/Alzheimer's Society/United Kingdom;MC_PC_17214/MRC_/Medical Research Council/United Kingdom\"}\n",
      "71 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32427279//?format=pubmed...\n",
      "{'PMID': '32427279', 'PT': 'Journal Article', 'OT': 'O  NNLM;*COVID19;*Corticosteroids;*SARSCOV2;*coronavirus;*outcomes', 'MH': 'Adrenal Cortex Hormones/administration & dosage/*therapeutic use;COVID19/*drug therapy;Female;Hospitalization/statistics & numerical data;Humans;Male;Methylprednisolone/administration & dosage/therapeutic use;Middle Aged;Multicenter Studies as Topic;DA 2020/12/15 06:00', 'SI': 'ClinicalTrials.gov/NCT04374071', 'TI': 'Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19.', 'GR': ''}\n",
      "72 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32942671//?format=pubmed...\n",
      "{'PMID': '32942671', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*COVID19;*SARSCoV2;*Zika virus;*antiviral;*dengue virus;*flavivirus;*ivermectin', 'MH': 'Animals;Antiviral Agents/*pharmacology;Betacoronavirus/*drug effects;COVID19;Cell Line;Chlorocebus aethiops;Coronavirus Infections/*drug therapy;Dengue/drug therapy;Dengue Virus/drug effects;HIV Infections/drug therapy;HIV Integrase/drug effects;HIV Integrase Inhibitors/pharmacology;HIV1/*drug effects;Humans;Ivermectin/*pharmacology;Pandemics;Pneumonia, Viral/*drug therapy;SARSCoV2;Vero Cells;Zika Virus/drug effects;Zika Virus Infection/drug therapy;DA 2020/09/29 06:00', 'SI': '', 'TI': 'Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?', 'GR': 'Senior Principal Research Fellowship APP1002486/APP1103050/National Health and '}\n",
      "73 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33550043//?format=pubmed...\n",
      "{'PMID': '33550043', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Favipiravir;Remdesivir;SARSCoV2;Vaccines', 'MH': '*Antiviral Agents/classification/pharmacology;*COVID19/drug therapy/prevention & control;*COVID19 Vaccines/classification/pharmacology;Humans;SARSCoV2/drug effects/physiology;Treatment Outcome;DA 2021/04/07 06:00', 'SI': '', 'TI': 'Effective drugs used to combat SARS-CoV-2 infection and the current status of ', 'GR': ''}\n",
      "74 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33153629//?format=pubmed...\n",
      "{'PMID': '33153629', 'PT': \"Journal Article;Multicenter Study;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't\", 'OT': '', 'MH': 'Aged;Antibodies, Monoclonal, Humanized/*administration & dosage;COVID19/*drug therapy/epidemiology/metabolism;DoseResponse Relationship, Drug;Female;GranulocyteMacrophage ColonyStimulating Factor/*antagonists & ;Humans;Infusions, Intravenous;Male;Middle Aged;Pandemics;*SARSCoV2;Treatment Outcome;DA 2020/12/15 06:00', 'SI': 'ClinicalTrials.gov/NCT04351152', 'TI': 'GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort ', 'GR': 'K12 CA090628/CA/NCI NIH HHS/United States;R01 AI110173/AI/NIAID NIH HHS/United States;R01 AI120698/AI/NIAID NIH HHS/United States'}\n",
      "75 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33243284//?format=pubmed...\n",
      "{'PMID': '33243284', 'PT': 'Journal Article;Randomized Controlled Trial', 'OT': 'O  NNLM;COVID19;Herb;M. communis;Myrtle;Persian medicine', 'MH': 'Adult;Aged;COVID19/complications/epidemiology/*therapy/virology;CaseControl Studies;Female;Humans;Iran/epidemiology;Male;Middle Aged;Mortality;Myrtus/*adverse effects/chemistry;Pandemics;Phytotherapy/*methods;Prognosis;Respiratory Distress Syndrome/etiology/therapy/virology;SARSCoV2/*genetics;Safety;Treatment Outcome;DA 2020/12/15 06:00', 'SI': '', 'TI': 'Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and ', 'GR': ''}\n",
      "76 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32733842//?format=pubmed...\n",
      "{'PMID': '32733842', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*COVID19;*SARSCoV2;*antiCOVID19 drugs;*chloroquine;*glucocorticoid;*lopinavir/ritonavir;*plasma therapy;*remdesivir', 'MH': 'Antiviral Agents/therapeutic use;*COVID19;Humans;*Pharmaceutical Preparations;Research;SARSCoV2;DA 2020/08/01 06:01', 'SI': '', 'TI': 'Progress in the Research and Development of Anti-COVID-19 Drugs.', 'GR': ''}\n",
      "77 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33510041//?format=pubmed...\n",
      "{'PMID': '33510041', 'PT': \"Journal Article;Multicenter Study;Observational Study;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*autoimmune diseases;*epidemiology;*health care;*outcome and process assessment;*outcome assessment;*therapeutics', 'MH': 'Adult;Brazil/epidemiology;COVID19/*immunology/*mortality/therapy;Critical Care/statistics & numerical data;Emergency Medical Services/statistics & numerical data;Female;Hospitalization/statistics & numerical data;Humans;Immunosuppression/*adverse effects;Male;Middle Aged;Prospective Studies;*Registries;Respiration, Artificial/statistics & numerical data;Rheumatic Diseases/*complications/immunology;DA 2021/02/07 06:00', 'SI': '', 'TI': 'High levels of immunosuppression are related to unfavourable outcomes in ', 'GR': ''}\n",
      "78 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32691699//?format=pubmed...\n",
      "{'PMID': '32691699', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;cardiovascular burden;chloroquine;hydroxychloroquine;remdesivir;review', 'MH': 'Adenosine Monophosphate/*analogs & derivatives/pharmacology;Alanine/*analogs & derivatives/pharmacology;Antiviral Agents/pharmacology;Azithromycin/*pharmacology;COVID19/*drug therapy/epidemiology;*Cardiovascular Diseases/chemically induced/prevention & control;*ChemicallyInduced Disorders/etiology/prevention & control;Chloroquine/*pharmacology;Drug Therapy, Combination/adverse effects/methods;Humans;SARSCoV2;DA 2021/04/13 06:00', 'SI': '', 'TI': 'Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: ', 'GR': ''}\n",
      "79 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32825816//?format=pubmed...\n",
      "{'PMID': '32825816', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Systematic Review\", 'OT': 'O  NNLM;*Clinical trial;*H1N1;*Influenza;*Pandemic;*Systematic review', 'MH': 'Antiviral Agents/*therapeutic use;Betacoronavirus;Bibliometrics;COVID19;*Compassionate Use Trials;Coronavirus Infections/drug therapy/epidemiology;CostBenefit Analysis;Global Health;Humans;Inappropriate Prescribing/*prevention & control;*Influenza A Virus, H1N1 Subtype;Influenza, Human/*drug therapy/epidemiology;*OffLabel Use;Pandemics;Pneumonia, Viral/drug therapy/epidemiology;Research Design;SARSCoV2;Treatment Outcome;DA 2020/09/04 06:00', 'SI': '', 'TI': 'Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009.', 'GR': '107834/Z/15/Z/WT_/Wellcome Trust/United Kingdom;106491/Z/14/Z/WT_/Wellcome Trust/United Kingdom'}\n",
      "80 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33434221//?format=pubmed...\n",
      "{'PMID': '33434221', 'PT': 'Clinical Trial;Journal Article;Observational Study', 'OT': '', 'MH': 'Adult;Aged;Aged, 80 and over;Biomarkers/blood;COVID19/*blood/pathology/therapy;Chemokine CXCL10/*blood;*Decision Support Systems, Clinical;Female;Humans;Male;Middle Aged;Practice Guidelines as Topic;DA 2021/01/20 06:00', 'SI': 'ClinicalTrials.gov/NCT04389645', 'TI': \"Observational cohort study of IP-10's potential as a biomarker to aid in \", 'GR': ''}\n",
      "81 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32243297//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32243297', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'Anesthesiologists;*Betacoronavirus;COVID19;Coronavirus Infections/drug therapy/*therapy/transmission;Critical Care;Humans;Pandemics;Pneumonia, Viral/drug therapy/*therapy/transmission;SARSCoV2;DA 2020/06/26 06:00', 'SI': '', 'TI': 'Coronaviruses and SARS-CoV-2: A Brief Overview.', 'GR': ''}\n",
      "82 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33130203//?format=pubmed...\n",
      "{'PMID': '33130203', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Antiviral;Clinical guidelines;In vitro;Pharmacokinetic;Viral clearance', 'MH': 'Amides/*administration & dosage;Antiviral Agents/*administration & dosage/therapeutic use;COVID19/*drug therapy/epidemiology/virology;Humans;Pandemics;Pyrazines/*administration & dosage;SARSCoV2/*drug effects/physiology;DA 2021/01/20 06:00', 'SI': '', 'TI': 'Role of favipiravir in the treatment of COVID-19.', 'GR': ''}\n",
      "83 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32828741//?format=pubmed...\n",
      "{'PMID': '32828741', 'PT': 'Case Reports;Journal Article', 'OT': 'O  NNLM;COVID19;Coronavirus;Methylene blue;Nacetyl cysteine;Treatment;Vitamin C', 'MH': 'Acetylcysteine/*therapeutic use;Ascorbic Acid/*therapeutic use;COVID19;*Clinical Trials, Phase I as Topic;Compassionate Use Trials;Coronavirus Infections/complications/*drug therapy;*Critical Illness;Female;Humans;Hypoxia/complications;Male;Methylene Blue/*therapeutic use;Middle Aged;Pandemics;Pneumonia, Viral/complications/*drug therapy;DA 2020/10/21 06:00', 'SI': 'ClinicalTrials.gov/NCT04370288', 'TI': 'Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of ', 'GR': ''}\n",
      "84 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32688395//?format=pubmed...\n",
      "{'PMID': '32688395', 'PT': 'Clinical Trial;Journal Article;Multicenter Study', 'OT': '', 'MH': 'Adult;Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors;Aged;Aged, 80 and over;AntiInflammatory Agents/therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/*complications/therapy;Female;Humans;Immunization, Passive;Leukemia, Lymphocytic, Chronic, BCell/*complications/therapy;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications/therapy;Protein Kinase Inhibitors/therapeutic use;SARSCoV2;Survival Analysis;Treatment Outcome;DA 2020/09/15 06:00', 'SI': '', 'TI': 'Outcomes of COVID-19 in patients with CLL: a multicenter international experience.', 'GR': 'P30 CA008748/CA/NCI NIH HHS/United States'}\n",
      "85 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33158234//?format=pubmed...\n",
      "{'PMID': '33158234', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*Traditional Chinese Medicines;*angiotensinconverting enzyme2;*antiviral;*epidemiology', 'MH': 'Betacoronavirus;COVID19;Coronavirus Infections/*epidemiology/*therapy;Humans;Medicine, Chinese Traditional;Pandemics;Pneumonia, Viral/*epidemiology/*therapy;SARSCoV2;DA 2020/11/21 06:00', 'SI': '', 'TI': 'COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional ', 'GR': ''}\n",
      "86 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32645632//?format=pubmed...\n",
      "{'PMID': '32645632', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Baricitinib;COVID19;Cytokine storm;JAKSTAT;Pharmaceutical care', 'MH': 'AngiotensinConverting Enzyme 2;Azetidines/pharmacology/*therapeutic use;Betacoronavirus/*immunology/metabolism;COVID19;Clinical Trials as Topic;Coronavirus Infections/complications/diagnosis/*drug therapy/immunology;Cytokine Release Syndrome/diagnosis/*drug therapy/immunology/virology;Cytokines/immunology/metabolism;Humans;Janus Kinase 1/antagonists & inhibitors/metabolism;Janus Kinase 2/antagonists & inhibitors/metabolism;Pandemics;PeptidylDipeptidase A/metabolism;Pneumonia, Viral/complications/diagnosis/*drug therapy/immunology;SARSCoV2;Severity of Illness Index;Signal Transduction/*drug effects/immunology;Sulfonamides/pharmacology/*therapeutic use;Treatment Outcome;Virus Assembly/drug effects;Virus Internalization/drug effects;DA 2020/08/25 06:00', 'SI': '', 'TI': 'Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target ', 'GR': ''}\n",
      "87 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33324210//?format=pubmed...\n",
      "{'PMID': '33324210', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;coronavirus;cytokine storm;fibrosis;macrophage', 'MH': 'DA 2020/12/17 06:01', 'SI': '', 'TI': 'Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019.', 'GR': ''}\n",
      "88 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33063092//?format=pubmed...\n",
      "{'PMID': '33063092', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*Aryl hydrocarbon receptor;*Indoleamine 2,3dioxygenase;*Kynurenine pathway;*Nicotinamide;*Poly (ADPribose) polymerase;*glucocorticoids', 'MH': 'Basic HelixLoopHelix Transcription Factors/metabolism;Betacoronavirus/drug effects;COVID19;Cell Line;Coronavirus Infections/*drug therapy/pathology;Cytokines/blood;Humans;Immunotherapy/methods;IndoleaminePyrrole 2,3,Dioxygenase/metabolism;Kynurenine/metabolism;Niacinamide/*pharmacology;Pandemics;Pneumonia, Viral/*drug therapy/pathology;Poly (ADPRibose) Polymerase1/*antagonists & inhibitors/metabolism;Poly(ADPribose) Polymerase Inhibitors/*pharmacology;Receptors, Aryl Hydrocarbon/metabolism;SARSCoV2;DA 2020/11/18 06:00', 'SI': '', 'TI': 'Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting ', 'GR': ''}\n",
      "89 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33232783//?format=pubmed...\n",
      "{'PMID': '33232783', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*Acute respiratory distress syndrome (ARDS);*COVID19;*Coronavirus;*Cytokine storm;*Dexamethasone;*Immune response;*SARSCoV2;*Treatment;*Vitamin D', 'MH': 'Adaptive Immunity;Animals;COVID19/*immunology/*physiopathology;Clinical Trials as Topic;Cytokine Release Syndrome/immunology/prevention & control;Disease Management;Humans;Immunity, Innate;Immunologic Factors;Inflammation/immunology/prevention & control;SARSCoV2;Vitamin D/*immunology/therapeutic use;Zoonoses/immunology;DA 2021/01/05 06:00', 'SI': '', 'TI': 'Putative roles of vitamin D in modulating immune response and immunopathology ', 'GR': ''}\n",
      "90 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32765502//?format=pubmed...\n",
      "{'PMID': '32765502', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*IL11;*IL6;*JAK;*STAT;*cytokine;*drug development;*interleukin;*structural biology', 'MH': 'Animals;Humans;*Interleukin11/chemistry/immunology/metabolism;*Interleukin6/chemistry/immunology/metabolism;Signal Transduction/*immunology;StructureActivity Relationship;DA 2021/04/07 06:00', 'SI': '', 'TI': 'Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted ', 'GR': ''}\n",
      "91 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33033561//?format=pubmed...\n",
      "{'PMID': '33033561', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19 disease;COVID19 pneumonia;Lung damage;Mesenchymal stem cell secretome;Mesenchymal stem cells;Stem/progenitor cells', 'MH': 'DA 2020/10/10 06:01', 'SI': '', 'TI': 'Perspectives on mesenchymal stem/progenitor cells and their derivates as potential ', 'GR': ''}\n",
      "92 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32499303//?format=pubmed...\n",
      "{'PMID': '32499303', 'PT': 'Journal Article;Research Support, N.I.H., Extramural', 'OT': 'O  NNLM;*COVID19;*COVID19 symptoms;*Famotidine;*PROMs;*SARSCoV2;*coronavirus;*outpatients', 'MH': 'Adult;Betacoronavirus/isolation & purification;COVID19;*Coronavirus Infections/diagnosis/drug therapy/physiopathology;DoseResponse Relationship, Drug;Drug Monitoring/*methods;Famotidine/*administration & dosage;Female;Histamine H2 Antagonists/administration & dosage;Humans;Male;Middle Aged;Oximetry/methods;*Pandemics;Patient Reported Outcome Measures;*Pneumonia, Viral/diagnosis/drug therapy/physiopathology;Retrospective Studies;SARSCoV2;Self Administration;Symptom Assessment/*methods;Treatment Outcome;DA 2020/08/25 06:00', 'SI': '', 'TI': 'Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised ', 'GR': 'P30 CA045508/CA/NCI NIH HHS/United States;R35 GM118182/GM/NIGMS NIH HHS/United States'}\n",
      "93 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33363098//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '33363098', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19;*SARSCoV2;*combination therapy;*economic impact;*treatment possibilities', 'MH': 'COVID19/*diagnosis/*epidemiology/*physiopathology/transmission;*COVID19 Vaccines;Humans;Personal Protective Equipment;SARSCoV2;DA 2021/01/21 06:00', 'SI': '', 'TI': 'Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global ', 'GR': ''}\n",
      "94 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33260370//?format=pubmed...\n",
      "{'PMID': '33260370', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;FDAapproved drugs;SARSCoV2;docking studies;spike glycoprotein', 'MH': 'Antiviral Agents/chemistry/*pharmacology;Computer Simulation;Drug Repositioning/*methods;Ligands;Membrane Fusion/drug effects;Models, Molecular;Molecular Docking Simulation;Protein Conformation;Spike Glycoprotein, Coronavirus/*chemistry/metabolism;Varenicline/chemistry/metabolism/pharmacology;DA 2020/12/19 06:00', 'SI': '', 'TI': 'Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for ', 'GR': 'PAACTI 312807/CONACYT/'}\n",
      "95 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33178016//?format=pubmed...\n",
      "{'PMID': '33178016', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Middle East respiratory syndrome coronavirus;coronavirus;coronavirus disease 2019;severe acute respiratory syndrome coronavirus2;therapeutic interventions;transmission', 'MH': 'DA 2020/11/13 06:01', 'SI': '', 'TI': 'COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future ', 'GR': ''}\n",
      "96 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32790733//?format=pubmed...\n",
      "{'PMID': '32790733', 'PT': 'Journal Article;Multicenter Study;Observational Study', 'OT': '', 'MH': 'Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use;Antimalarials/*therapeutic use;Azithromycin/therapeutic use;*Betacoronavirus;COVID19;Child;Child, Preschool;Coronavirus Infections/*drug therapy/mortality/virology;Drug Therapy, Combination;Female;FollowUp Studies;Hospitalization;Humans;Hydroxychloroquine/*therapeutic use;Infant;Infant, Newborn;Intensive Care Units;Interleukin6/antagonists & inhibitors;KaplanMeier Estimate;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/mortality/virology;Retrospective Studies;SARSCoV2;Treatment Outcome;Young Adult;DA 2020/08/29 06:00', 'SI': 'ClinicalTrials.gov/NCT04347993', 'TI': 'Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational ', 'GR': 'P30 CA016672/CA/NCI NIH HHS/United States;UL1 TR003167/TR/NCATS NIH HHS/United States'}\n",
      "97 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32727107//?format=pubmed...\n",
      "{'PMID': '32727107', 'PT': 'Case Reports', 'OT': 'O  NNLM;COVID19;acute respiratory distress syndrome (ARDS);case report;cytokines;immunotherapy;inflammation', 'MH': 'Administration, Intravenous;Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use;Antiviral Agents/therapeutic use;Betacoronavirus/isolation & purification;COVID19;Combined Modality Therapy;Coronavirus Infections/*complications;Dyspnea/diagnosis;Humans;Hypoxia/diagnosis;Male;Middle Aged;Noninvasive Ventilation/methods;Pandemics;Pneumonia, Viral/*complications;Respiratory Distress Syndrome/diagnostic imaging/*etiology/therapy;SARSCoV2;Tomography, XRay Computed/methods;Treatment Outcome;DA 2020/08/07 06:00', 'SI': '', 'TI': 'Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab ', 'GR': ''}\n",
      "98 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32766535//?format=pubmed...\n",
      "{'PMID': '32766535', 'PT': 'Journal Article', 'OT': 'O  NNLM;Coronavirus disease 2019;Cytokine release syndrome;Tocilizumab', 'MH': 'DA 2020/08/09 06:01', 'SI': '', 'TI': 'Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine ', 'GR': ''}\n",
      "99 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33249292//?format=pubmed...\n",
      "{'PMID': '33249292', 'PT': 'Letter', 'OT': '', 'MH': 'DA 2020/11/30 06:00', 'SI': '', 'TI': 'Repurposing medications.', 'GR': ''}\n",
      "100 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32451271//?format=pubmed...\n",
      "{'PMID': '32451271', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*cardiac complications;*cardiac injury;*coronavirus disease2019;*inflammatory factors;*pneumonia', 'MH': '*COVID19;*Cardiovascular Diseases/diagnosis/epidemiology/etiology;*Coronavirus;*Coronavirus Infections/diagnosis/epidemiology/therapy;Humans;Pandemics;SARSCoV2;DA 2021/04/29 06:00', 'SI': '', 'TI': 'Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications.', 'GR': ''}\n",
      "101 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32492298//?format=pubmed...\n",
      "{'PMID': '32492298', 'PT': 'Comment;Editorial', 'OT': '', 'MH': '*Betacoronavirus;COVID19;*Coronavirus Infections/prevention & control;Humans;Hydroxychloroquine;*Pandemics;*Pneumonia, Viral/prevention & control;SARSCoV2;DA 2020/08/08 06:00', 'SI': '', 'TI': 'Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.', 'GR': ''}\n",
      "102 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33365326//?format=pubmed...\n",
      "{'PMID': '33365326', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;immunity;junctional complex;nutrients;vitamin C;vitamin D;zinc', 'MH': 'DA 2020/12/29 06:01', 'SI': '', 'TI': 'Zinc, Vitamin D and Vitamin C: Perspectives for COVID-19 With a Focus on Physical ', 'GR': ''}\n",
      "103 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33154452//?format=pubmed...\n",
      "{'PMID': '33154452', 'PT': 'Journal Article', 'OT': '', 'MH': 'Antibodies, Monoclonal, Humanized/*administration & dosage/*pharmacology/therapeutic ;COVID19;Coronavirus Infections/*drug therapy/*mortality;Female;*Hospital Mortality;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral/*drug therapy/*mortality;DA 2020/12/01 06:00', 'SI': '', 'TI': 'Impact of tocilizumab administration on mortality in severe COVID-19.', 'GR': ''}\n",
      "104 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33509275//?format=pubmed...\n",
      "{'PMID': '33509275', 'PT': 'Clinical Trial Protocol;Journal Article', 'OT': 'O  NNLM;Adaptive trial;COVID19;Clinical trial;Coronavirus;Platform trial;SARSCoV2', 'MH': 'AntiBacterial Agents/therapeutic use;Antiviral Agents/therapeutic use;COVID19/*therapy;Clinical Trials, Phase IV as Topic;CommunityAcquired Infections/*therapy;EvidenceBased Medicine;Humans;Multicenter Studies as Topic;Pneumonia/*therapy;PointofCare Systems;Randomized Controlled Trials as Topic;SARSCoV2;DA 2021/02/09 06:00', 'SI': 'ClinicalTrials.gov/NCT02735707', 'TI': 'Implementation of the Randomized Embedded Multifactorial Adaptive Platform for ', 'GR': 'K23 GM132688/GM/NIGMS NIH HHS/United States'}\n",
      "105 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33465165//?format=pubmed...\n",
      "{'PMID': '33465165', 'PT': 'Journal Article;Research Support, N.I.H., Extramural', 'OT': '', 'MH': 'Animals;COVID19/drug therapy/*prevention & control;Chlorocebus aethiops/virology;Humans;Hydroxychloroquine/*pharmacology;SARSCoV2/*drug effects;Serine Endopeptidases/*drug effects;Spike Glycoprotein, Coronavirus/*drug effects/metabolism;Vero Cells/virology;Virus Internalization/*drug effects;DA 2021/02/18 06:00', 'SI': '', 'TI': 'Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.', 'GR': 'R01 AI129868/AI/NIAID NIH HHS/United States'}\n",
      "106 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32896649//?format=pubmed...\n",
      "{'PMID': '32896649', 'PT': 'Letter', 'OT': 'O  NNLM;*COVID19;*Clinical trials;*Cytokine storm;*Dexamethasone;*SARSCoV2;*Therapeutics', 'MH': 'DA 2020/09/09 06:01', 'SI': '', 'TI': 'Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary ', 'GR': ''}\n",
      "107 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32612666//?format=pubmed...\n",
      "{'PMID': '32612666', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;ACE2;COVID19;Diabetes mellitus (DM);SARSCoV2', 'MH': 'DA 2020/07/03 06:01', 'SI': '', 'TI': 'SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done?', 'GR': ''}\n",
      "108 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32516704//?format=pubmed...\n",
      "{'PMID': '32516704', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Cancer;Covid19;Immunotherapy;Mortality;NSCLC', 'MH': 'Betacoronavirus/isolation & purification;COVID19;Coronavirus Infections/drug therapy/immunology/mortality/*physiopathology/*therapy;Humans;Neoplasms/diagnosis/mortality/*therapy/*virology;Pandemics;Pneumonia, Viral/immunology/mortality/*physiopathology/*therapy;Respiratory Distress Syndrome/mortality/physiopathology/virology;SARSCoV2;DA 2020/07/30 06:00', 'SI': '', 'TI': 'Cancer and COVID-19: Unmasking their ties.', 'GR': ''}\n",
      "109 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33033884//?format=pubmed...\n",
      "{'PMID': '33033884', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Coronavirus;Mesenchymal stem cells;Umbilical cord;Wharton’s jelly', 'MH': 'COVID19/*therapy;Clinical Trials as Topic;Humans;Immunomodulation;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells;Pandemics;Respiratory Distress Syndrome/virology;Umbilical Cord/*cytology;Wharton Jelly/*cytology;DA 2021/01/16 06:00', 'SI': '', 'TI': 'Umbilical cord: an allogenic tissue for potential treatment of COVID-19.', 'GR': ''}\n",
      "110 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32863636//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '32863636', 'PT': 'Journal Article', 'OT': 'O  NNLM;Acute respiratory distress syndrome;COVID19;Coronavirus;Cytokine storm;Immunosuppressants', 'MH': 'DA 2020/08/31 06:01', 'SI': '', 'TI': 'Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management ', 'GR': ''}\n",
      "111 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33238464//?format=pubmed...\n",
      "{'PMID': '33238464', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;HIV;USFDA;drug repurposing/reprofiling;zidovudine', 'MH': 'DA 2020/11/27 06:01', 'SI': '', 'TI': 'Drug Repurposing Approaches to Combating Viral Infections.', 'GR': 'P51 OD011132/OD/NIH HHS/United States;R01 DA052845/DA/NIDA NIH HHS/United States;R01 DA042524/DA/NIDA NIH HHS/United States;P30 MH062261/MH/NIMH NIH HHS/United States;R01AI129745, P30MH062261, R01DA042524, R01DA050169 , P51OD011133/NH/NIH HHS/United '}\n",
      "112 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33152192//?format=pubmed...\n",
      "{'PMID': '33152192', 'PT': 'Journal Article;Systematic Review', 'OT': 'O  NNLM;*chloroquine;*hydroxychloroquine;*coronavirus;*systematic review;*clinical trial;*pandemics;*SARSCoV2', 'MH': 'Antiviral Agents/adverse effects/pharmacology/*therapeutic use;Betacoronavirus/*drug effects/physiology;COVID19;Chloroquine/adverse effects/pharmacology/*therapeutic use;Clinical Trials as Topic;Compassionate Use Trials;Coronavirus Infections/*drug therapy;Cytokine Release Syndrome/drug therapy;Drug Repositioning;Humans;Hydroxychloroquine/adverse effects/pharmacology/*therapeutic use;Multicenter Studies as Topic;Pandemics;Pneumonia, Viral/*drug therapy;Randomized Controlled Trials as Topic;Registries;SARSCoV2;Treatment Outcome;Virus Replication/drug effects;DA 2020/11/20 06:00', 'SI': '', 'TI': 'Chloroquine and its derivatives in the management of COVID-19: A scoping review.', 'GR': ''}\n",
      "113 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32472459//?format=pubmed...\n",
      "{'PMID': '32472459', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Algorithm;COVID19;Management;SarsCoV2', 'MH': 'Algorithms;*Antiviral Agents/immunology/pharmacology;Betacoronavirus/isolation & purification;COVID19;COVID19 Testing;Clinical Laboratory Techniques/*methods;*Coronavirus Infections/diagnosis/drug therapy/epidemiology/immunology/therapy;Critical Pathways;*Cytokine Release Syndrome/diagnosis/drug therapy/etiology;Humans;*Pandemics;Patient Care Team/*organization & administration;*Pneumonia, Viral/epidemiology/immunology/therapy;SARSCoV2;DA 2020/06/25 06:00', 'SI': '', 'TI': 'Treatment algorithm for COVID-19: a multidisciplinary point of view.', 'GR': ''}\n",
      "114 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32430627//?format=pubmed...\n",
      "{'PMID': '32430627', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*Acute myocardial injury;*Aging;*COVID19;*Cardiovascular system;*Frailty;*SARSCoV2', 'MH': 'Age Factors;Aged;*Betacoronavirus;COVID19;Cardiovascular Diseases/epidemiology/*virology;Coronavirus Infections/*complications/epidemiology;Female;Humans;Italy;Male;Middle Aged;Pandemics;Pneumonia, Viral/*complications/epidemiology;Risk Factors;SARSCoV2;DA 2020/08/18 06:00', 'SI': '', 'TI': 'COVID-19-associated cardiovascular morbidity in older adults: a position paper from ', 'GR': \"828984/Horizon 2020 Framework Programme/International;ETHERNA 161/16/Fondazione Cassa di Risparmio di Pisa (IT)/International;Dipartimenti di Eccellenza Program (20182022)/Ministero dell'Istruzione, ;2018/FIL/International\"}\n",
      "115 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32574236//?format=pubmed...\n",
      "{'PMID': '32574236', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;GS5734;RdRp;SARSCoV2;remdesivir', 'MH': 'DA 2020/06/24 06:01', 'SI': '', 'TI': 'Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a ', 'GR': ''}\n",
      "116 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32545799//?format=pubmed...\n",
      "{'PMID': '32545799', 'PT': \"Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*antiviral drug combinations;*antivirals;*broadspectrum antivirals', 'MH': 'Amodiaquine/pharmacology;Animals;Antiviral Agents/*pharmacology;Betacoronavirus/*drug effects;COVID19;Caco2 Cells;Cell Line, Tumor;Chlorocebus aethiops;Coronavirus Infections/*drug therapy/therapy;Drug Therapy, Combination;Emetine/pharmacology;HEK293 Cells;HT29 Cells;Homoharringtonine/pharmacology;Humans;Immune Sera/immunology;Immunization, Passive/methods;Nelfinavir/pharmacology;Neutralization Tests/*methods;Pandemics;Pneumonia, Viral/*drug therapy;Pyrans/pharmacology;Pyrroles/pharmacology;SARSCoV2;Vero Cells;DA 2020/07/01 06:00', 'SI': '', 'TI': 'Potential Antiviral Options against SARS-CoV-2 Infection.', 'GR': 'MOBTT39/Estonian Research Competency Council/International'}\n",
      "117 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33416933//?format=pubmed...\n",
      "{'PMID': '33416933', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19 inflammasomes;*Chloroquine;*Hydroxychloroquine', 'MH': 'AntiInflammatory Agents/*therapeutic use;COVID19/*drug therapy;Chloroquine/*therapeutic use;Cytokine Release Syndrome;Humans;Hydroxychloroquine/*therapeutic use;Inflammasomes/*drug effects;NLR Family, Pyrin DomainContaining 3 Protein/*drug effects/genetics;DA 2021/05/14 06:00', 'SI': '', 'TI': 'Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?', 'GR': ''}\n",
      "118 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32880807//?format=pubmed...\n",
      "{'PMID': '32880807', 'PT': 'Comment;Letter', 'OT': '', 'MH': '*Betacoronavirus;COVID19;*Coronavirus Infections;Humans;Immunomodulation;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/10/02 06:00', 'SI': '', 'TI': 'Comment on: \"Pharmaco-Immunomodulatory Therapy in COVID-19\".', 'GR': ''}\n",
      "119 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32654006//?format=pubmed...\n",
      "{'PMID': '32654006', 'PT': 'Journal Article', 'OT': 'O  NNLM;*Acute respiratory distress syndrome;*Acute respiratory failure;*Coronavirus;*Mesenchymal stromal cells;*Pharmacologic therapy', 'MH': 'Antioxidants/therapeutic use;Ascorbic Acid/therapeutic use;COVID19/*drug therapy;Citrulline/therapeutic use;Drug Therapy/*trends;Glycoproteins/therapeutic use;Humans;Mesenchymal Stem Cells;Pandemics;Peptides, Cyclic/therapeutic use;Pyridones/therapeutic use;Pyrimidines/therapeutic use;Receptors, Tumor Necrosis Factor, Type I/antagonists & inhibitors/therapeutic use;Respiratory Distress Syndrome/*drug therapy;Steroids/therapeutic use;Trypsin Inhibitors/therapeutic use;DA 2020/12/29 06:00', 'SI': '', 'TI': 'Emerging pharmacological therapies for ARDS: COVID-19 and beyond.', 'GR': 'MC_G1002460/MRC_/Medical Research Council/United Kingdom;MR/M009149/1/MRC_/Medical Research Council/United Kingdom'}\n",
      "120 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32629768//?format=pubmed...\n",
      "{'PMID': '32629768', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;MERS;SARS;guideline;lopinavir;recommendation;ritonavir', 'MH': 'DA 2020/07/08 06:01', 'SI': '', 'TI': 'Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current ', 'GR': ''}\n",
      "121 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33531826//?format=pubmed...\n",
      "{'PMID': '33531826', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;NLRP3;SARSCoV2;cGASSTING;coronavirus;immune evasion;innate immune system;nucleic acid sensing', 'MH': 'DA 2021/02/04 06:01', 'SI': '', 'TI': 'Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus ', 'GR': ''}\n",
      "122 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32613089//?format=pubmed...\n",
      "{'PMID': '32613089', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID;Pneumonia;Radiotherapy', 'MH': 'DA 2020/07/03 06:01', 'SI': 'ClinicalTrials.gov/NCT04380818', 'TI': 'Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: ', 'GR': ''}\n",
      "123 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32388976//?format=pubmed...\n",
      "{'PMID': '32388976', 'PT': 'Journal Article', 'OT': '', 'MH': 'Animals;Betacoronavirus/chemistry/*physiology;COVID19;Coronavirus Infections/*epidemiology/physiopathology/*prevention & control/virology;Cysteine Proteinase Inhibitors/chemistry/therapeutic use;Drug Repositioning;Humans;Mice;Neglected Diseases/*prevention & control;Pandemics/*prevention & control;Pneumonia, Viral/*epidemiology/physiopathology/*prevention & control/virology;RNA, Viral/immunology;SARSCoV2;Spike Glycoprotein, Coronavirus/immunology;Vaccination;Viral Vaccines/immunology/therapeutic use;Virus Replication/drug effects;DA 2020/08/04 06:00', 'SI': '', 'TI': 'COVID-19: Living through Another Pandemic.', 'GR': ''}\n",
      "124 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32277351//?format=pubmed...\n",
      "{'PMID': '32277351', 'PT': 'Journal Article', 'OT': '', 'MH': 'COVID19;Contraindications, Drug;Coronavirus Infections/*immunology;Dermatitis, Atopic/drug therapy;Hidradenitis Suppurativa/drug therapy;Humans;*Immunomodulation;Immunosuppressive Agents/*therapeutic use;*Pandemics;Pneumonia, Viral/*immunology;Psoriasis/drug therapy;Skin Diseases/*drug therapy/immunology;DA 2020/06/13 06:00', 'SI': '', 'TI': 'Managing Cutaneous Immune-Mediated Diseases During the\\xa0COVID-19 Pandemic.', 'GR': ''}\n",
      "125 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33338232//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '33338232', 'PT': \"Journal Article;Randomized Controlled Trial;Research Support, NonU.S. Gov't\", 'OT': '', 'MH': 'Adult;Ambulatory Care/*methods/trends;Antimalarials/administration & dosage;Antiviral Agents/*administration & dosage;COVID19/*diagnosis/*drug therapy;Carbamates/*administration & dosage;DoubleBlind Method;Drug Therapy, Combination;Female;FollowUp Studies;Humans;Hydroxychloroquine/administration & dosage;Imidazoles/*administration & dosage;Male;Middle Aged;Pyrrolidines/*administration & dosage;Sofosbuvir/*administration & dosage;Treatment Outcome;Valine/administration & dosage/*analogs & derivatives;DA 2021/02/24 06:00', 'SI': '', 'TI': 'Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a ', 'GR': ''}\n",
      "126 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32838164//?format=pubmed...\n",
      "{'PMID': '32838164', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;ACE2;COVID19;Cardiovascular complications;Furin;SARSCoV2;Spike protein', 'MH': 'DA 2020/08/25 06:00', 'SI': '', 'TI': 'Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular ', 'GR': ''}\n",
      "127 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33493590//?format=pubmed...\n",
      "{'PMID': '33493590', 'PT': 'Journal Article', 'OT': '', 'MH': 'DA 2021/01/26 06:00', 'SI': 'ClinicalTrials.gov/NCT04333693', 'TI': 'Outcomes After Vascular Surgery Procedures in Patients with COVID-19 Infection: A ', 'GR': ''}\n",
      "128 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33348292//?format=pubmed...\n",
      "{'PMID': '33348292', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Antiviral;COVID19;Immune system;Interferon;Pandemic;Severe acute respiratory syndrome coronavirus 2', 'MH': 'Animals;Antiviral Agents/*pharmacology/*therapeutic use;COVID19/*drug therapy/virology;Humans;Interferon Type I/*pharmacology/*therapeutic use;Pandemics/prevention & control;SARSCoV2/*drug effects;DA 2021/02/03 06:00', 'SI': '', 'TI': 'Interferon-inducer antivirals: Potential candidates to combat COVID-19.', 'GR': ''}\n",
      "129 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32766608//?format=pubmed...\n",
      "{'PMID': '32766608', 'PT': 'Preprint', 'OT': '', 'MH': 'DA 2020/08/09 06:01', 'SI': '', 'TI': 'Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury ', 'GR': 'R21 AI129455/AI/NIAID NIH HHS/United States;DP2 AI138242/AI/NIAID NIH HHS/United States;R01 AI151059/AI/NIAID NIH HHS/United States;K08 CA230156/CA/NCI NIH HHS/United States;WT_/Wellcome Trust/United Kingdom;R01 AI146165/AI/NIAID NIH HHS/United States'}\n",
      "130 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32784543//?format=pubmed...\n",
      "{'PMID': '32784543', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;ACE2;Ang 17;Bartter’s syndrome;Gitelman’s syndrome;endosome pH;gene mutations;glycosylation;phenotype', 'MH': 'AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/pharmacology/therapeutic use;Animals;Bartter Syndrome/*genetics/metabolism/pathology;COVID19;Coronavirus Infections/*drug therapy;Endosomes/drug effects/metabolism;Gitelman Syndrome/*genetics/metabolism/pathology;Humans;Hydroxychloroquine/pharmacology/therapeutic use;Pandemics;PeptidylDipeptidase A/*metabolism;*Phenotype;Pneumonia, Viral/*drug therapy;DA 2020/08/21 06:00', 'SI': '', 'TI': \"Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes \", 'GR': ''}\n",
      "131 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32923016//?format=pubmed...\n",
      "{'PMID': '32923016', 'PT': 'Journal Article', 'OT': 'O  NNLM;Coronavirus disease 2019;Efficacy;Safety;Triazavirin', 'MH': 'DA 2020/09/15 06:01', 'SI': '', 'TI': 'Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot ', 'GR': ''}\n",
      "132 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33227708//?format=pubmed...\n",
      "{'PMID': '33227708', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Azithromycin;COVID19;Chloroquine/hydroxychloroquine;Interferons;Treatment;Vaccine', 'MH': 'Antiviral Agents/*therapeutic use;Azithromycin/*therapeutic use;COVID19/*prevention & control;COVID19 Vaccines/*therapeutic use;Chloroquine/*therapeutic use;Humans;Hydroxychloroquine/therapeutic use;Interferons/*therapeutic use;Treatment Outcome;DA 2021/01/01 06:00', 'SI': '', 'TI': 'Prevention and treatment of COVID-19: Focus on interferons, ', 'GR': ''}\n",
      "133 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32571007//?format=pubmed...\n",
      "{'PMID': '32571007', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*combination drug delivery;*coronavirus disease 2019;*immunopathology;*nanomedicine;*repurposed nanotechnology;*severe acute respiratory syndrome coronavirus 2 structure;*targeted therapeutics;*vaccine adjuvant nanoparticles;*vaccine nanocarriers', 'MH': 'COVID19;COVID19 Vaccines;Coronavirus Infections/immunology/*prevention & control/therapy/virology;Humans;Mass Vaccination/adverse effects/*methods;Nanotechnology/*methods;Pandemics/*prevention & control;Pneumonia, Viral/immunology/*prevention & control/therapy/virology;Viral Vaccines/immunology/*therapeutic use;DA 2020/09/02 06:00', 'SI': '', 'TI': 'Nanotechnology for COVID-19: Therapeutics and Vaccine Research.', 'GR': ''}\n",
      "134 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32380316//?format=pubmed...\n",
      "{'PMID': '32380316', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;ACE2 receptor;COVID19;Convalescent plasma;Coronavirus;Cytokines;Intravenous immunoglobulins;Neutralizing antibodies;SARSCov2', 'MH': 'Antibodies, Neutralizing/*therapeutic use;Betacoronavirus;COVID19;Clinical Trials as Topic;Coronavirus Infections/immunology/*therapy;Humans;Immunization, Passive;Lymphocytes/immunology;Pandemics;Pneumonia, Viral/immunology/*therapy;Retrospective Studies;SARSCoV2;DA 2020/06/11 06:00', 'SI': '', 'TI': 'Convalescent plasma in Covid-19: Possible mechanisms of action.', 'GR': ''}\n",
      "135 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33171706//?format=pubmed...\n",
      "{'PMID': '33171706', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;Plasmodium;antimalarial agents;kinase inhibitors;kinases;malaria', 'MH': 'Animals;Antimalarials/*pharmacology;Calcium/metabolism;Casein Kinase I/metabolism;Culicidae;Drug Design;Drug Discovery/*trends;Drug Resistance;Glycogen Synthase Kinase 3/metabolism;Humans;Imidazoles/pharmacology;Inhibitory Concentration 50;Life Cycle Stages/drug effects;MAP Kinase Signaling System;Malaria/*drug therapy;Phosphotransferases/chemistry;Plasmodium/*drug effects/enzymology;Protein Kinase Inhibitors/*pharmacology;Pyridines/pharmacology;DA 2021/04/22 06:00', 'SI': '', 'TI': 'An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.', 'GR': ''}\n",
      "136 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32645974//?format=pubmed...\n",
      "{'PMID': '32645974', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;ACE2;COVID19;SARSCoV2;cardiovascular disease (CVD);cardiovascular system;hydroxychloroquine;therapeutics', 'MH': 'DA 2020/07/11 06:01', 'SI': '', 'TI': 'SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, ', 'GR': 'K99 DK120876/DK/NIDDK NIH HHS/United States;19CDA34490009/American Heart Association/;K99DK120876/DK/NIDDK NIH HHS/United States'}\n",
      "137 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32503877//?format=pubmed...\n",
      "{'PMID': '32503877', 'PT': 'Journal Article;Research Support, N.I.H., Intramural', 'OT': '', 'MH': 'Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors/metabolism;Aged;Aged, 80 and over;Benzamides/*pharmacology/*therapeutic use;*Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy/virology;Critical Illness;Female;FollowUp Studies;Humans;Inflammation/drug therapy/virology;Interleukin6/metabolism;Male;Middle Aged;Monocytes/metabolism;Pandemics;Pneumonia, Viral/*drug therapy/virology;Prospective Studies;Pyrazines/*pharmacology/*therapeutic use;Respiration, Artificial;SARSCoV2;Treatment Outcome;DA 2020/06/20 06:00', 'SI': '', 'TI': 'Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.', 'GR': ''}\n",
      "138 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33075713//?format=pubmed...\n",
      "{'PMID': '33075713', 'PT': 'Clinical Trial;Journal Article;Multicenter Study', 'OT': 'O  NNLM;COVID19;COVID19 pandemic;Coronavirus;Interleukin 6;Multicenter trial;Tocilizumab', 'MH': 'Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects;COVID19/*drug therapy/mortality;Female;Humans;Injections, Subcutaneous;Male;Middle Aged;Prospective Studies;*SARSCoV2;DA 2020/12/16 06:00', 'SI': '', 'TI': 'Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective ', 'GR': ''}\n",
      "139 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33511518//?format=pubmed...\n",
      "{'PMID': '33511518', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*COVID19;*Cellbased therapy;*Personalized medicine;*Stem cell', 'MH': 'COVID19/*drug therapy/immunology/*therapy/virology;*Cell and TissueBased Therapy;Humans;*Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells/immunology;SARSCoV2/pathogenicity;DA 2021/03/03 06:00', 'SI': '', 'TI': 'Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.', 'GR': ''}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "140 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32507883//?format=pubmed...\n",
      "{'PMID': '32507883', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*AngiotensinConverting Enzyme 2;*Covid19;*ReninAngiotensin System;*SARSCoV2', 'MH': 'AngiotensinConverting Enzyme 2;AngiotensinConverting Enzyme Inhibitors/*pharmacology;Animals;Betacoronavirus/*metabolism;COVID19;Coronavirus Infections/*drug therapy/metabolism/virology;Humans;Pandemics;PeptidylDipeptidase A/*metabolism;Pneumonia, Viral/*drug therapy/metabolism/virology;ReninAngiotensin System/*physiology;SARSCoV2;DA 2020/06/17 06:00', 'SI': '', 'TI': 'Covid-19: the renin-angiotensin system imbalance hypothesis.', 'GR': ''}\n",
      "141 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32564908//?format=pubmed...\n",
      "{'PMID': '32564908', 'PT': 'Journal Article', 'OT': 'O  NNLM;Angiotensin converting enzyme inhibitors;Angiotensin receptor blockers;COVID 19;Neprilysin;Renin angiotensin system;Vitamin D', 'MH': 'AngiotensinConverting Enzyme 2;Betacoronavirus/*physiology;COVID19;*Coronavirus Infections/metabolism/mortality/virology;Humans;Mortality;*Pandemics;*PeptidylDipeptidase A/genetics/metabolism;*Pneumonia, Viral/metabolism/mortality/virology;ReninAngiotensin System/*physiology;*Risk Factors;SARSCoV2;Virus Internalization;DA 2020/08/19 06:00', 'SI': '', 'TI': 'COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System ', 'GR': ''}\n",
      "142 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33094446//?format=pubmed...\n",
      "{'PMID': '33094446', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Clinical trials;Immunity;Zinc', 'MH': 'DA 2020/10/24 06:00', 'SI': '', 'TI': 'Zinc and COVID-19: Basis of Current Clinical Trials.', 'GR': ''}\n",
      "143 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32848774//?format=pubmed...\n",
      "{'PMID': '32848774', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;chloroquine;coronavirus;hydroxychloroquine;potential risk', 'MH': 'DA 2020/08/28 06:01', 'SI': '', 'TI': 'Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their ', 'GR': ''}\n",
      "144 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32304488//?format=pubmed...\n",
      "{'PMID': '32304488', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'Adenosine Monophosphate/analogs & derivatives;Alanine/analogs & derivatives;Antibodies, Monoclonal, Humanized;Antiviral Agents/*adverse effects/therapeutic use;Betacoronavirus;COVID19;Coronavirus Infections/*drug therapy;Drug Interactions;*Drug Monitoring;Glucocorticoids;Humans;Hydroxychloroquine;Immunosuppressive Agents/*adverse effects/therapeutic use;Pandemics;Pneumonia, Viral/*drug therapy;Protease Inhibitors;SARSCoV2;*Transplant Recipients;DA 2020/05/27 06:00', 'SI': '', 'TI': 'Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: ', 'GR': ''}\n",
      "145 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33162266//?format=pubmed...\n",
      "{'PMID': '33162266', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Coronavirus;Infectious disease;Pregnancy', 'MH': 'Algorithms;COVID19/*diagnosis/*therapy;Emergency Medicine;Female;Humans;Postpartum Period;Pregnancy;Pregnancy Complications, Infectious/*diagnosis/*therapy;*Pregnancy Outcome;DA 2021/02/26 06:00', 'SI': '', 'TI': 'COVID-19 in pregnancy and the puerperium: A review for emergency physicians.', 'GR': ''}\n",
      "146 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32943404//?format=pubmed...\n",
      "{'PMID': '32943404', 'PT': 'Journal Article;Randomized Controlled Trial', 'OT': '', 'MH': 'Adult;Aged;AntiInflammatory Agents/*administration & dosage;COVID19/*drug therapy;Female;Hospitalization;Humans;Injections, Intravenous;Male;Methylprednisolone/*administration & dosage;Middle Aged;Pulse Therapy, Drug;Severity of Illness Index;SingleBlind Method;DA 2021/02/09 06:00', 'SI': '', 'TI': 'Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 ', 'GR': ''}\n",
      "147 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32947136//?format=pubmed...\n",
      "{'PMID': '32947136', 'PT': \"Journal Article;Research Support, NonU.S. Gov't;Review\", 'OT': 'O  NNLM;*Coronavirus;*RNA virus;*Respiratory disease;*SARSCoV2;*SARSCoV2 inhibitors', 'MH': 'Amino Acid Sequence;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/epidemiology;*Drug Discovery;Drug Repositioning;Humans;Pandemics;Protease Inhibitors/*therapeutic use;SARSCoV2/*drug effects;DA 2020/12/15 06:00', 'SI': '', 'TI': 'Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.', 'GR': 'U19 AI142759/AI/NIAID NIH HHS/United States'}\n",
      "148 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32911430//?format=pubmed...\n",
      "{'PMID': '32911430', 'PT': 'Journal Article', 'OT': 'O  NNLM;*COVID19;*IL6;*SARSCoV2;*Vitamin C;*drug discovery', 'MH': 'Animals;Ascorbic Acid/pharmacology/*therapeutic use;COVID19/*drug therapy/*prevention & control;Coronavirus;Female;Humans;Interleukin6/metabolism;Male;Pandemics;SARSCoV2;Vitamins/pharmacology/*therapeutic use;DA 2020/12/15 06:00', 'SI': '', 'TI': 'Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?', 'GR': ''}\n",
      "149 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32284951//?format=pubmed...\n",
      "{'PMID': '32284951', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;SARSCoV2;hydroxychloroquine;lopinavir/ritonavir;remdesivir', 'MH': 'DA 2020/04/15 06:01', 'SI': '', 'TI': 'Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.', 'GR': ''}\n",
      "150 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32452888//?format=pubmed...\n",
      "{'PMID': '32452888', 'PT': 'Journal Article;Observational Study', 'OT': '', 'MH': 'Aged;*Betacoronavirus;COVID19;Cohort Studies;Comorbidity;Coronavirus Infections/complications/*mortality/therapy;Critical Illness;Female;Georgia/epidemiology;Hospital Mortality;Humans;Intensive Care Units;Male;Middle Aged;Organ Dysfunction Scores;Pandemics;Pneumonia, Viral/complications/*mortality/therapy;*Respiration, Artificial;Respiratory Distress Syndrome/etiology/*mortality/therapy;SARSCoV2;Socioeconomic Factors;DA 2020/09/04 06:00', 'SI': '', 'TI': 'ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease ', 'GR': 'K23 AI134182/AI/NIAID NIH HHS/United States;UL1 TR002378/TR/NCATS NIH HHS/United States'}\n",
      "151 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32547788//?format=pubmed...\n",
      "{'PMID': '32547788', 'PT': 'Journal Article', 'OT': 'O  NNLM;Infectious diseases;Medical research', 'MH': 'DA 2020/06/18 06:01', 'SI': '', 'TI': 'Off-label therapy targeting pathogenic inflammation in COVID-19.', 'GR': ''}\n",
      "152 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33029758//?format=pubmed...\n",
      "{'PMID': '33029758', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;SARSCoV2;angiotensinconverting enzyme 2;cytokine storm;multiple organ failure;reninangiotensin system', 'MH': 'AngiotensinConverting Enzyme 2/*metabolism;Biomarkers/metabolism;COVID19/metabolism/*physiopathology;Cytokine Release Syndrome/metabolism/physiopathology/*virology;Cytokines/metabolism;Humans;Inflammation/metabolism/physiopathology/*virology;Multiple Organ Failure/metabolism/physiopathology/*virology;Receptors, Coronavirus/*metabolism;Severity of Illness Index;DA 2021/01/16 06:00', 'SI': '', 'TI': 'Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure ', 'GR': ''}\n",
      "153 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32494931//?format=pubmed...\n",
      "{'PMID': '32494931', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;*Acute respiratory distress syndrome;*COVID19;*Cell therapy;*Coronavirus;*Severe acute respiratory syndrome;*Therapeutic approaches', 'MH': 'Adrenal Cortex Hormones/therapeutic use;Antibodies, Monoclonal/therapeutic use;Antiviral Agents/therapeutic use;BCG Vaccine/therapeutic use;Betacoronavirus/genetics/*immunology;COVID19;Coronavirus Infections/*drug therapy/*immunology/prevention & ;Humans;Immunization, Passive/methods;Immunotherapy, Adoptive/methods;Janus Kinase Inhibitors/therapeutic use;Mesenchymal Stem Cell Transplantation/methods;Nanomedicine/methods;Pandemics/prevention & control;Pneumonia, Viral/*drug therapy/*immunology/prevention & control/virology;SARSCoV2;Serine Proteinase Inhibitors/therapeutic use;DA 2020/07/08 06:00', 'SI': '', 'TI': 'Novel therapeutic approaches for treatment of COVID-19.', 'GR': ''}\n",
      "154 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32663575//?format=pubmed...\n",
      "{'PMID': '32663575', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Cytokine storm;Dexamethasone;Hydroxychloroquine;IL1 inhibitors;IL6 inhibitors;JAK inhibitors;Mast cell stabilizers', 'MH': 'Adrenal Cortex Hormones/pharmacology;AntiInflammatory Agents/pharmacology;Betacoronavirus/immunology/pathogenicity;COVID19;Coronavirus/immunology/pathogenicity;Coronavirus Infections/*drug therapy/*immunology/pathology/virology;Cytokines/immunology;Dexamethasone/*pharmacology;Humans;Pandemics;Pneumonia, Viral/*drug therapy/*immunology/pathology/virology;Respiratory Distress Syndrome/drug therapy;SARSCoV2;DA 2020/09/30 06:00', 'SI': '', 'TI': 'Tackling the cytokine storm in COVID-19, challenges and hopes.', 'GR': ''}\n",
      "155 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33227287//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '33227287', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Repurposed drugs;SARSCoV2;Therapeutic targets;Vaccines', 'MH': 'Adrenal Cortex Hormones/*therapeutic use;Animals;Antiviral Agents/*therapeutic use;COVID19/*drug therapy/epidemiology/*therapy;Drug Repositioning;Epidemics;Humans;Immunization, Passive;*Medicine, Ayurvedic;*Medicine, Chinese Traditional;*SARSCoV2/immunology;Viral Vaccines;DA 2020/12/30 06:00', 'SI': '', 'TI': 'A comprehensive review on potential therapeutics interventions for COVID-19.', 'GR': ''}\n",
      "156 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33180830//?format=pubmed...\n",
      "{'PMID': '33180830', 'PT': \"Journal Article;Observational Study;Research Support, NonU.S. Gov't\", 'OT': '', 'MH': 'Aged;Aged, 80 and over;Betacoronavirus;COVID19;Coronavirus Infections/*mortality;Extracorporeal Membrane Oxygenation;Female;Germany/epidemiology;*Hospital Mortality;Humans;Intensive Care Units;Male;Middle Aged;Models, Statistical;Pandemics;Pneumonia, Viral/*mortality;Respiration, Artificial;Retrospective Studies;SARSCoV2;Tertiary Healthcare;DA 2020/11/24 06:00', 'SI': '', 'TI': 'COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted ', 'GR': ''}\n",
      "157 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32290348//?format=pubmed...\n",
      "{'PMID': '32290348', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;SARSCoV2;chloroquine;hydroxychloroquine;lopinavir/ritonavir;remdesivir;repurposing', 'MH': 'DA 2020/04/16 06:01', 'SI': '', 'TI': 'COVID-19: A Brief Overview of the Discovery Clinical Trial.', 'GR': ''}\n",
      "158 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33041620//?format=pubmed...\n",
      "{'PMID': '33041620', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;AntiHMGCR;HIV myositis;Immune checkpoint inhibitors;Immunosuppression;Inflammatory myopathy;Malignancyassociated myositis;Overlap myositis;SARSCoV2', 'MH': 'DA 2020/10/13 06:01', 'SI': '', 'TI': 'Secondary Causes of Myositis.', 'GR': ''}\n",
      "159 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32835666//?format=pubmed...\n",
      "{'PMID': '32835666', 'PT': 'Journal Article;Research Support, N.I.H., Extramural', 'OT': 'O  NNLM;*ACE2;*Arrhythmia;*COVID19;*Cardiovascular;*Sex differences;*Thrombosis', 'MH': 'AngiotensinConverting Enzyme 2/genetics;Arrhythmias, Cardiac/complications/epidemiology;COVID19/complications/*epidemiology/genetics;Cardiovascular Diseases/complications/*epidemiology;Disease Progression;Disease Susceptibility;Endothelium, Vascular/pathology;Female;Humans;Inflammation;Male;Microcirculation;Obesity/complications;Risk Factors;*Sex Factors;Smoking;Thrombosis/complications/epidemiology;DA 2021/01/05 06:00', 'SI': '', 'TI': 'Sex differences underlying preexisting cardiovascular disease and cardiovascular ', 'GR': 'R01 HL131182/HL/NHLBI NIH HHS/United States;R01 HL147586/HL/NHLBI NIH HHS/United States'}\n",
      "160 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33227067//?format=pubmed...\n",
      "{'PMID': '33227067', 'PT': 'Editorial', 'OT': '', 'MH': 'DA 2020/11/24 06:01', 'SI': '', 'TI': 'Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of ', 'GR': ''}\n",
      "161 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32894364//?format=pubmed...\n",
      "{'PMID': '32894364', 'PT': 'Journal Article', 'OT': 'O  NNLM;Bacteria;COVID19;Coinfection;Haemophilus influenzae;SARSCoV2;Staphylococcus aureus;Streptococcus pneumoniae', 'MH': 'DA 2020/09/08 06:01', 'SI': '', 'TI': 'Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia ', 'GR': ''}\n",
      "162 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32391667//?format=pubmed...\n",
      "{'PMID': '32391667', 'PT': 'Journal Article;Randomized Controlled Trial', 'OT': '', 'MH': '*Betacoronavirus/isolation & purification;COVID19;China;Coronavirus Infections/diagnostic imaging/drug therapy;Humans;*Hydroxychloroquine/therapeutic use;Pandemics;Pilot Projects;Pneumonia, Viral/diagnostic imaging/drug therapy;RNA, Viral/isolation & purification;SARSCoV2;Treatment Outcome;DA 2020/05/19 06:00', 'SI': 'ClinicalTrials.gov/NCT04261517', 'TI': '[A pilot study of hydroxychloroquine in treatment of patients with moderate ', 'GR': ''}\n",
      "163 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32533292//?format=pubmed...\n",
      "{'PMID': '32533292', 'PT': 'Comment;Letter', 'OT': 'O  NNLM;*Anticoagulation;*COVID19;*Immune therapy;*Strategy', 'MH': 'Betacoronavirus;COVID19;*Coronavirus;*Coronavirus Infections;Humans;*Pandemics;*Pneumonia, Viral;SARSCoV2;DA 2020/07/10 06:00', 'SI': '', 'TI': 'Targeting the immunology of coronavirus disease-19: synchronization creates ', 'GR': ''}\n",
      "164 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32789802//?format=pubmed...\n",
      "{'PMID': '32789802', 'PT': 'Historical Article;Journal Article;Review', 'OT': 'O  NNLM;*1918 Influenza Pandemic;*Antiviral Drugs;*COVID19;*Coronavirus;*Pandemics;*SARS Virus;*Stem Cells;*Vaccines', 'MH': 'COVID19/pathology/prevention & control/*therapy/virology;*Cell and TissueBased Therapy;History, 20th Century;Humans;Immunization, Passive;Influenza Pandemic, 19181919/history;Pandemics/history;Regenerative Medicine/history;SARSCoV2/pathogenicity;DA 2021/03/03 06:00', 'SI': '', 'TI': 'Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons ', 'GR': 'R01NS090962, R01NS102395, and R21NS109575/National Institutes of Health (US)/'}\n",
      "165 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32838323//?format=pubmed...\n",
      "{'PMID': '32838323', 'PT': 'Journal Article', 'OT': '', 'MH': 'DA 2020/08/25 06:01', 'SI': 'ClinicalTrials.gov/NCT04347993', 'TI': 'Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre ', 'GR': ''}\n",
      "166 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33194450//?format=pubmed...\n",
      "{'PMID': '33194450', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;IL6;SARSCOV2;Tocilizumab', 'MH': 'DA 2020/11/17 06:01', 'SI': '', 'TI': 'The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a ', 'GR': ''}\n",
      "167 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33376955//?format=pubmed...\n",
      "{'PMID': '33376955', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;ACE2;COVID‐19;Interferon;SARS‐CoV‐2;Treatment', 'MH': 'DA 2020/12/31 06:01', 'SI': '', 'TI': 'Type I interferon: From innate response to treatment for COVID-19.', 'GR': ''}\n",
      "168 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33472855//?format=pubmed...\n",
      "{'PMID': '33472855', 'PT': \"Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, NonU.S. Gov't\", 'OT': '', 'MH': 'Adolescent;Adult;Aged;Aged, 80 and over;AntiInflammatory Agents/*therapeutic use;Antibodies, Monoclonal, Humanized/*therapeutic use;COVID19/diagnosis/*drug therapy/mortality/therapy;Critical Illness;Female;FollowUp Studies;Hospitalization;Humans;Infusions, Intravenous;Male;Middle Aged;Respiration, Artificial;Severity of Illness Index;Treatment Outcome;Young Adult;DA 2021/01/28 06:00', 'SI': 'ClinicalTrials.gov/NCT04403685', 'TI': 'Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or ', 'GR': ''}\n",
      "169 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33010945//?format=pubmed...\n",
      "{'PMID': '33010945', 'PT': 'Editorial', 'OT': '', 'MH': 'DA 2020/10/05 06:01', 'SI': '', 'TI': 'SGLT-2 inhibitors as cardioprotective agents in COVID-19.', 'GR': ''}\n",
      "170 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33532594//?format=pubmed...\n",
      "{'PMID': '33532594', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID‐19;SARS‐CoV‐2;artificial intelligence;combinatory treatment;digital medicine;drug development;drug interactions', 'MH': 'DA 2021/02/04 06:01', 'SI': '', 'TI': 'IDentif.AI: Rapidly optimizing combination therapy design against severe Acute ', 'GR': ''}\n",
      "171 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33510484//?format=pubmed...\n",
      "{'PMID': '33510484', 'PT': 'News', 'OT': '', 'MH': 'Antibodies, Monoclonal/therapeutic use;Biological Products/*therapeutic use;COVID19/drug therapy;Cell and TissueBased Therapy;Drug Approval;Humans;Immunoconjugates/therapeutic use;Internationality;Rare Diseases/drug therapy;United States;United States Food and Drug Administration;DA 2021/03/10 06:00', 'SI': '', 'TI': 'Refreshing the biologic pipeline 2020.', 'GR': ''}\n",
      "172 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32664990//?format=pubmed...\n",
      "{'PMID': '32664990', 'PT': 'Letter', 'OT': 'O  NNLM;*Adjuvant therapies;*Atorvastatin;*COVID19;*Critical care;*Emerging disease;*Immunomodulators;*Statins', 'MH': 'Aged;Atorvastatin/*therapeutic use;COVID19;Coronavirus Infections/drug therapy/mortality;Female;Hospital Mortality;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral/mortality;Retrospective Studies;Treatment Outcome;DA 2020/07/17 06:00', 'SI': '', 'TI': 'Atorvastatin associated with decreased hazard for death in COVID-19 patients ', 'GR': ''}\n",
      "173 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33279860//?format=pubmed...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '33279860', 'PT': 'Journal Article', 'OT': 'O  NNLM;Breath analysis;COVID19;Intensive care;Mechanical ventilation;Metabolomics', 'MH': 'Aged;Area Under Curve;Breath Tests;COVID19/*pathology/virology;Critical Illness;Discriminant Analysis;Female;Humans;LeastSquares Analysis;Male;Metabolomics/*methods;Middle Aged;Pilot Projects;Principal Component Analysis;Prospective Studies;ROC Curve;Respiration, Artificial;Respiratory Distress Syndrome/pathology;SARSCoV2/isolation & purification;Volatile Organic Compounds/*analysis/metabolism;DA 2021/01/29 06:00', 'SI': '', 'TI': 'Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study.', 'GR': ''}\n",
      "174 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33191206//?format=pubmed...\n",
      "{'PMID': '33191206', 'PT': 'Journal Article;Review', 'OT': '', 'MH': 'Adenosine Monophosphate/analogs & derivatives/chemistry/pharmacology/therapeutic use;Alanine/analogs & derivatives/chemistry/pharmacology/therapeutic use;AntiInflammatory Agents/chemistry/pharmacology/*therapeutic use;Antioxidants/chemistry/pharmacology/*therapeutic use;Antiviral Agents/chemistry/pharmacology/*therapeutic use;COVID19/*drug therapy;Drug Repositioning/*methods/trends;Humans;SARSCoV2/*drug effects;Treatment Outcome;Virus Internalization/drug effects;DA 2021/01/14 06:00', 'SI': '', 'TI': 'Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A ', 'GR': ''}\n",
      "175 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32535870//?format=pubmed...\n",
      "{'PMID': '32535870', 'PT': 'Journal Article', 'OT': '', 'MH': 'Betacoronavirus/*pathogenicity;COVID19;Coronavirus Infections/*complications/virology;Humans;Infection Control;Neoplasms/complications/epidemiology/*surgery;Pandemics;Patient Education as Topic;Pneumonia, Viral/*complications/virology;Population Health;Practice Guidelines as Topic/*standards;SARSCoV2;Surgical Oncology/*standards;DA 2020/07/23 06:00', 'SI': '', 'TI': 'Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively ', 'GR': 'P30 CA023108/CA/NCI NIH HHS/United States'}\n",
      "176 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33126054//?format=pubmed...\n",
      "{'PMID': '33126054', 'PT': \"Clinical Trial;Journal Article;Research Support, NonU.S. Gov't\", 'OT': 'O  NNLM;*Biomarker;*COVID19;*Inflammation;*Micronutrient;*Trace element', 'MH': 'Adult;Age Factors;Aged;Aged, 80 and over;COVID19/*blood/diagnosis/*mortality;CrossSectional Studies;DiseaseFree Survival;Female;Humans;Male;Middle Aged;PSelectin/*blood;Predictive Value of Tests;SARSCoV2/*metabolism;Survival Rate;Zinc/*blood;DA 2021/01/13 06:00', 'SI': '', 'TI': 'Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as ', 'GR': ''}\n",
      "177 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33041814//?format=pubmed...\n",
      "{'PMID': '33041814', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19 proposed therapy;Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2);convalescent plasma;pandemic;therapeutic challenges', 'MH': 'DA 2020/10/13 06:01', 'SI': '', 'TI': 'Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future ', 'GR': ''}\n",
      "178 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33212828//?format=pubmed...\n",
      "{'PMID': '33212828', 'PT': 'Journal Article', 'OT': 'O  NNLM;COVID19;SARSCoV2;child;neoplasm', 'MH': 'DA 2020/11/21 06:01', 'SI': '', 'TI': 'Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report ', 'GR': 'AAP flash Covid19/Agence Nationale de la Recherche/'}\n",
      "179 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33435568//?format=pubmed...\n",
      "{'PMID': '33435568', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;NETosis;NOXdependent and NOXindependent;chronic obstructive pulmonary disease (COPD);innate immunity neutrophils;neutrophil extracellular traps (NETs);pathogenesis', 'MH': 'DA 2021/01/14 06:01', 'SI': '', 'TI': 'Orchestration of Neutrophil Extracellular Traps (Nets), a Unique Innate Immune ', 'GR': ''}\n",
      "180 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/33249060//?format=pubmed...\n",
      "{'PMID': '33249060', 'PT': \"Journal Article;Research Support, N.I.H., Extramural;Research Support, NonU.S. Gov't;Research Support, U.S. Gov't, NonP.H.S.\", 'OT': 'O  NNLM;*Antiviral;*COVID19;*Coronavirus;*Cytokine;*Cytokine storm;*DHODH;*PTC299;*SARSCoV2', 'MH': 'Animals;Antiviral Agents/*pharmacology;COVID19/drug therapy;Carbamates/*pharmacology;Carbazoles/*pharmacology;Chlorocebus aethiops;Cytokine Release Syndrome/drug therapy;Cytokines/*antagonists & inhibitors/immunology;HeLa Cells;Humans;Inflammation/drug therapy/virology;Oxidoreductases Acting on CHCH Group Donors/*antagonists & inhibitors;SARSCoV2/*drug effects;Vero Cells;Virus Replication/*drug effects;DA 2021/01/05 06:00', 'SI': '', 'TI': 'The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction ', 'GR': 'UL1 TR001430/TR/NCATS NIH HHS/United States;R01 AI148784/AI/NIAID NIH HHS/United States;R37 AI147868/AI/NIAID NIH HHS/United States;HL007035T32/NH/NIH HHS/United States;R35 GM122468/GM/NIGMS NIH HHS/United States;TL1 TR001440/TR/NCATS NIH HHS/United States'}\n",
      "181 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32713677//?format=pubmed...\n",
      "{'PMID': '32713677', 'PT': 'Journal Article', 'OT': 'O  NNLM;*Interstitial pneumonia;*Intubation;*SARSCov2', 'MH': 'Aged;Antibodies, Monoclonal, Humanized/*administration & dosage;Betacoronavirus/immunology;COVID19;CaseControl Studies;Coronavirus Infections/complications/*drug therapy/immunology/mortality;Female;Hospital Mortality;Humans;Infusions, Intravenous;Interleukin6/immunology/metabolism;Male;Middle Aged;Pandemics;Pneumonia, Viral/complications/*drug therapy/immunology/mortality;Receptors, Interleukin6/*antagonists & inhibitors/metabolism;Respiratory Distress Syndrome/diagnosis/*drug therapy/immunology/mortality;Retrospective Studies;SARSCoV2;Severity of Illness Index;Survival Analysis;Treatment Outcome;DA 2020/10/28 06:00', 'SI': '', 'TI': 'Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe ', 'GR': ''}\n",
      "182 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32623267//?format=pubmed...\n",
      "{'PMID': '32623267', 'PT': 'Journal Article;Review', 'OT': 'O  NNLM;COVID19;Coronavirus;Pandemic;Review;SARSCoV2', 'MH': '*Betacoronavirus/genetics/immunology/physiology;COVID19;Coronavirus Infections/diagnosis/epidemiology/immunology/*virology;Genome, Viral/genetics;HIV Infections/complications;Humans;Pandemics;Pneumonia, Viral/diagnosis/epidemiology/immunology/*virology;SARSCoV2;Virus Replication;DA 2020/08/18 06:00', 'SI': '', 'TI': 'Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus ', 'GR': ''}\n",
      "183 row added!\n",
      "processing https://pubmed.ncbi.nlm.nih.gov/32574237//?format=pubmed...\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-1-3fae6caadb09>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[1;31m#test import a py file\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 2\u001b[1;33m \u001b[1;32mfrom\u001b[0m \u001b[0mmylib\u001b[0m \u001b[1;32mimport\u001b[0m \u001b[0mPubMedTerms_useList\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32m~\\JupyterSpace\\CTO\\mylib\\PubMedTerms_useList.py\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m    103\u001b[0m     \u001b[0mpagelink\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mBase_URL\u001b[0m\u001b[1;33m+\u001b[0m\u001b[0mPMID\u001b[0m\u001b[1;33m+\u001b[0m\u001b[1;34m\"//?format=pubmed\"\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    104\u001b[0m     \u001b[0mprint\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m\"processing \"\u001b[0m\u001b[1;33m+\u001b[0m\u001b[0mpagelink\u001b[0m\u001b[1;33m+\u001b[0m\u001b[1;34m\"...\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 105\u001b[1;33m     \u001b[0mcontent\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mpage_content_body\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mpagelink\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    106\u001b[0m     \u001b[0mnew_row\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mcreate_new_row\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mcontent\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    107\u001b[0m     \u001b[0mprint\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mnew_row\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\JupyterSpace\\CTO\\mylib\\PubMedTerms_useList.py\u001b[0m in \u001b[0;36mpage_content_body\u001b[1;34m(URL)\u001b[0m\n\u001b[0;32m     51\u001b[0m \u001b[1;32mdef\u001b[0m \u001b[0mpage_content_body\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mURL\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     52\u001b[0m     \u001b[1;34m'''give an URL, will return the text of the body tag'''\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 53\u001b[1;33m     \u001b[0mresponse\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mrequests\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mget\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mURL\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     54\u001b[0m     \u001b[0mpage\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mresponse\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtext\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     55\u001b[0m     \u001b[0msoup\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mBeautifulSoup\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mpage\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\requests\\api.py\u001b[0m in \u001b[0;36mget\u001b[1;34m(url, params, **kwargs)\u001b[0m\n\u001b[0;32m     74\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     75\u001b[0m     \u001b[0mkwargs\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msetdefault\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'allow_redirects'\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;32mTrue\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 76\u001b[1;33m     \u001b[1;32mreturn\u001b[0m \u001b[0mrequest\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'get'\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mparams\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     77\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     78\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\requests\\api.py\u001b[0m in \u001b[0;36mrequest\u001b[1;34m(method, url, **kwargs)\u001b[0m\n\u001b[0;32m     59\u001b[0m     \u001b[1;31m# cases, and look like a memory leak in others.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     60\u001b[0m     \u001b[1;32mwith\u001b[0m \u001b[0msessions\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mSession\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0msession\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 61\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0msession\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mmethod\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mmethod\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0murl\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     62\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     63\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\requests\\sessions.py\u001b[0m in \u001b[0;36mrequest\u001b[1;34m(self, method, url, params, data, headers, cookies, files, auth, timeout, allow_redirects, proxies, hooks, stream, verify, cert, json)\u001b[0m\n\u001b[0;32m    528\u001b[0m         }\n\u001b[0;32m    529\u001b[0m         \u001b[0msend_kwargs\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mupdate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msettings\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 530\u001b[1;33m         \u001b[0mresp\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mprep\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0msend_kwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    531\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    532\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\requests\\sessions.py\u001b[0m in \u001b[0;36msend\u001b[1;34m(self, request, **kwargs)\u001b[0m\n\u001b[0;32m    641\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    642\u001b[0m         \u001b[1;31m# Send the request\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 643\u001b[1;33m         \u001b[0mr\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0madapter\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    644\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    645\u001b[0m         \u001b[1;31m# Total elapsed time of the request (approximately)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\requests\\adapters.py\u001b[0m in \u001b[0;36msend\u001b[1;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[0;32m    437\u001b[0m         \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    438\u001b[0m             \u001b[1;32mif\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mchunked\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 439\u001b[1;33m                 resp = conn.urlopen(\n\u001b[0m\u001b[0;32m    440\u001b[0m                     \u001b[0mmethod\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mrequest\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mmethod\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    441\u001b[0m                     \u001b[0murl\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0murl\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36murlopen\u001b[1;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, **response_kw)\u001b[0m\n\u001b[0;32m    668\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    669\u001b[0m             \u001b[1;31m# Make the request on the httplib connection object.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 670\u001b[1;33m             httplib_response = self._make_request(\n\u001b[0m\u001b[0;32m    671\u001b[0m                 \u001b[0mconn\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    672\u001b[0m                 \u001b[0mmethod\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36m_make_request\u001b[1;34m(self, conn, method, url, timeout, chunked, **httplib_request_kw)\u001b[0m\n\u001b[0;32m    379\u001b[0m         \u001b[1;31m# Trigger any extra validation we need to do.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    380\u001b[0m         \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 381\u001b[1;33m             \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_validate_conn\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mconn\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    382\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[1;33m(\u001b[0m\u001b[0mSocketTimeout\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mBaseSSLError\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    383\u001b[0m             \u001b[1;31m# Py2 raises this as a BaseSSLError, Py3 raises it as socket timeout.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\urllib3\\connectionpool.py\u001b[0m in \u001b[0;36m_validate_conn\u001b[1;34m(self, conn)\u001b[0m\n\u001b[0;32m    976\u001b[0m         \u001b[1;31m# Force connect early to allow us to validate the connection.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    977\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mgetattr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mconn\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m\"sock\"\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m  \u001b[1;31m# AppEngine might not have  `.sock`\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 978\u001b[1;33m             \u001b[0mconn\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mconnect\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    979\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    980\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mconn\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mis_verified\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\urllib3\\connection.py\u001b[0m in \u001b[0;36mconnect\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    307\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mconnect\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    308\u001b[0m         \u001b[1;31m# Add certificate verification\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 309\u001b[1;33m         \u001b[0mconn\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_new_conn\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    310\u001b[0m         \u001b[0mhostname\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mhost\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    311\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\urllib3\\connection.py\u001b[0m in \u001b[0;36m_new_conn\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    157\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    158\u001b[0m         \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 159\u001b[1;33m             conn = connection.create_connection(\n\u001b[0m\u001b[0;32m    160\u001b[0m                 \u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_dns_host\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mport\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mextra_kw\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    161\u001b[0m             )\n",
      "\u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\urllib3\\util\\connection.py\u001b[0m in \u001b[0;36mcreate_connection\u001b[1;34m(address, timeout, source_address, socket_options)\u001b[0m\n\u001b[0;32m     72\u001b[0m             \u001b[1;32mif\u001b[0m \u001b[0msource_address\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     73\u001b[0m                 \u001b[0msock\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mbind\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msource_address\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 74\u001b[1;33m             \u001b[0msock\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mconnect\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msa\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     75\u001b[0m             \u001b[1;32mreturn\u001b[0m \u001b[0msock\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     76\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "#test import a py file\n",
    "from mylib import PubMedTerms_useList\n",
    "# test result: work well"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
